

INDEX

Clinical Chemistry: Principles, Procedures, Correlations, 5E

Page numbers in *italics* denote figures; those followed by a *t* denote tables

A

- α_1 -fetoprotein (AFP)
 - in amniotic fluid, 555
 - characteristics of, 190*t*, 195
 - as tumor marker, 608, 612
- α_1 -acid glycoprotein (orosomuroid), 190*t*, 195
- α_1 -antichymotrypsin (α_1 -ACT), 190*t*, 195–196
- α_1 -antitrypsin
 - characteristics of, 190*t*, 194–195
 - deficiency of, 208, 209
- ABCA1 transporter, 289–290
- Absolute specificity, 239
- Absorbance (A)
 - in automated analysis measurement, 136–137
 - and Beer's Law, 25, 92
 - delta, 26
 - of hemoglobin, 354
 - and percent transmittance, 682*t*–683*t*
- Absorption
 - of copper, 369
 - of drugs, 571–572
 - of D-xylose, 545, 550–551
 - of energy, 91, 92
 - in fluorometry, 98
 - intestinal, 549, 550–551
 - of iron, 366
 - of lipids, 288
 - ultraviolet, 205
 - of zinc, 370
- Absorptivity, molar (ϵ), 26, 92–93
- Abused drugs, 598–601, 690*t*–691*t*
 - amphetamines, 599–600
 - anabolic steroids, 600
 - cannabinoids, 600
 - cocaine, 600–601
 - opiates, 601
 - phencyclidine, 601
 - prevalence of, 599*t*
 - sedative hypnotics, 601
- ACA (Automated Clinical Analyzer) Star
 - automated column chromatography in, 135
 - calibration of, 139
 - delay stations in, 136
 - history of, 125
 - mixing in, 134–135
 - photometer in, 137

- reagents in, 132–133, 134
- specimen measurement and delivery in, 132
- Accidents, 45–46
- Accreditation, 35
- Accuracy
 - estimation of, 65–66
 - in lipid analysis, 298, 304–305
 - of wavelength, 96
- Acetaminophen, 481, 597–598
- Acetylcholinesterase (AChE), 555, 596
- Acetylsalicylic acid, 597
- Acid elution stain, 392
- Acid phosphatase (ACP), 253–255
 - assay for, 254
 - diagnostic significance of, 254
 - reference range for, 255
 - sources of error, 255
 - tissue sources of, 254
- Acid-base balance
 - assessment of, 346, 348–349
 - blood gas measurement, 353–358
 - buffer systems in, 344–345
 - disorders of, 348–349
 - kidneys in, 345, 346, 347, 348, 523
 - lungs in, 345
 - maintenance of H⁺, 344
 - oxygen and gas exchange in, 349–353
 - in pediatric patients, 659
 - quality assurance in assessments, 358–361
- Acidemia, 185, 348
- Acidosis
 - defined, 344
 - ketoacidosis, 271
 - lactic, 336
 - metabolic (nonrespiratory), 324, 348, 349, 358
 - in pediatric patients, 659
 - renal tubular, 530
 - respiratory, 348, 349
- Acids (*See also* Acid-base balance)
 - concentrations of, 677t
 - defined, 344
 - excretion of, 523
 - pH of, 9, 344
- ACP (*See* Acid phosphatase)
- Acridinium esters, 152
- Acromegaly, 404–405, 526
- ACTH (*See* Adrenocorticotrophic hormone)
- Activated clotting time (ACT), 175–176
- Activation energy, 238, 239
- Activators, 237, 241
- Active sites of enzymes, 237
- Active transport, 315
- Activity units, 243
- Actual percent oxyhemoglobin (O₂Hb), 353–354
- Acute coronary syndrome, 501–503 (*See also* Coronary heart disease)

- Acute intermittent porphyria (AIP), 379, 380
- Acute renal failure (See Renal failure)
- Acute-phase proteins/reactants
 - α -antitrypsin, 190*t*, 194–195
 - C-reactive protein, 190*t*, 198, 636, 667
 - fibrinogen, 190*t*, 198, 509, 513*t*
 - in immunity, 667
 - in protein electrophoresis, 210
- Adaptive immune system, 667
- Adenohypophysis (anterior pituitary), 400
- Adenomas
 - adrenal, 417–418
 - aldo-producing, 417
 - toxic, 453
- Adenosine triphosphate (ATP), 265–266
- Adenylate kinase (AK), 247
- ADH (See Antidiuretic hormone)
- Adhesion molecules, 607
- Administration routes of drugs, 571
- ADP (ALA dehydratase deficiency porphyria), 379–380
- Adrenal function, 413–429
 - adrenal cortex in, 414–424
 - adrenal insufficiency, 418–419
 - adrenal medulla in, 424–426, 428–429
 - androgen excess, 423–424
 - catecholamines in, 424–426, 428, 429
 - causes of sympathetic hyperactivity, 426
 - congenital adrenal hyperplasia, 415–418, 666
 - cortex steroidogenesis, 414–415
 - Cushing's syndrome, 419–422
 - embryology and anatomy in, 413–414
 - hypercortisolism, 419–423
 - incidentaloma, 428, 429
 - in pediatric patients, 665
 - pheochromocytoma, 424, 426, 428
 - primary aldosteronism, 417–418, 429
- Adrenal imaging, 417–418
- Adrenal insufficiency, 418–419
- Adrenal vein sampling, 418
- Adrenocarcinoma, 429
- Adrenocorticotrophic hormone (ACTH)
 - and cortisol, 418, 421–422, 665
 - and diurnal rhythms, 402
 - in glucose regulation, 267
 - in steroid hormone biosynthesis, 414–415
 - and vasopressin, 402
- Adsorption chromatography, 108
- Adsorption in immunoassays, 155
- Advanced glycation end products (AGEs), 648
- Advia analyzers, 125, 128*t*, 138
- Aerobic pathway, 265, 266
- Aeroset analyzers, 125, 128*t*
- Affinity
 - of antibodies, 146–147
 - of hemoglobin and oxygen, 353
- Affinity chromatography, 277

- Affinity constant (K_a), 147
- AFP (See α_1 -fetoprotein)
- A/G (albumin-globulin) ratio, 205
- Agammaglobulinemia, 668
- Agarose gel
 - in electrophoresis, 106, 208, 300
 - in immune precipitation, 147–150
- Age
 - and atherosclerosis, 501
 - gestational, 557
 - and reference intervals, 57, 58
 - and testosterone levels, 440
- Aging, 643–652
 - biochemical and physiologic changes in, 645–650
 - analytes, 646*t*
 - cardiovascular function, 650
 - diabetes and insulin resistance, 647–648
 - electrolytes, 649
 - endocrine function, 645–647
 - enzymes, 650
 - hepatic function, 649
 - lipids, 650
 - pulmonary function, 649
 - renal function, 648–649
 - defined, 643
 - diseases and disorders associated with, 645*t*
 - and laboratory results, 650–652
 - exercise and nutrition in, 652
 - preanalytical variables in, 651
 - reference intervals, 650–651
 - therapeutic drug monitoring, 651–652
 - and leading causes of death, 646*t*
 - theories of, 644–645
- AIP (acute intermittent porphyria), 379, 380
- Airborne pathogens, 39
- Air-displacement pipets, 13
- ALA (See Aminolevulinic acid)
- ALA dehydratase deficiency porphyria (ADP), 379–380
- Alanine aminotransferase (ALT), 251, 484
- Albumin
 - A/G ratio, 205
 - in cerebrospinal fluid, 215, 562
 - characteristics of, 190*t*, 193–194
 - fractionation of, 205–207
 - in liver disease, 485
 - microalbuminuria, 213, 279, 525–526, 533
 - in nutritional assessment, 634
 - in pediatric patients, 663
- Albumin/creatinine ratio, 526
- Alcoholism
 - effect on analytes, 29, 31
 - and ethanol, 590
 - and γ -glutamyltransferase, 255
- Alcohols
 - common indicators of abuse, 590*t*

- determination of, 591–592
 - toxic effects of, 481, 589–590
- Aldehydes, 263
- Aldo-ism, 417
- Aldo-producing adenoma (APA), 417
- Aldose, 263
- Aldosterone (Aldo)
- abnormal production of, 417
 - in congenital adrenal hyperplasia, 415–416
 - hyperaldosteronism, 416–418, 429
 - hypoaldosteronism, 416
 - plasma aldosterone, 416
 - in renal function, 520, 521
 - synthesis of, 414, 415
- Aldosteronism, 416–418
- diagnosis of, 417–418, 429
 - types of, 416, 417
- Alimentary tract, 549
- Alkalemia, 323, 348
- Alkaline phosphatase (ALP), 252–253
- in chemiluminescent assays, 153
 - isoenzymes, 252–253
 - in liver disease, 484
 - reference intervals of, 57, 253
- Alkalosis
- defined, 344
 - nonrespiratory (metabolic), 348, 349, 358
 - in pediatric patients, 659
 - respiratory, 348, 349
- Alkaptonuria, 183, 184, 526
- Allantoin, 227, 228
- Allosteric sites, 237
- ALP (See Alkaline phosphatase)
- ALT (alanine aminotransferase), 251, 484
- Altman-Bland diagrams, 53
- α_2 -macroglobulin, 190*t*, 196–197
- Amenorrhea, 434–435
- AMI (See Myocardial infarctions)
- Amino acids, 180–186
- aminoacidopathies, 180, 182–186
 - alkaptonuria, 183, 184
 - argininosuccinic aciduria, 186
 - citrullinemia, 186
 - cystinuria, 186
 - homocystinuria, 185–186, 529
 - isovaleric acidemia, 184, 185
 - maple syrup urine disease, 184–185
 - phenylketonuria, 182–183
 - tyrosinemia, 183–184
 - analysis of, 186
 - charge of, 189
 - in hemoglobin structure, 383–384
 - metabolism of, 180, 181
 - structure of, 180, 181*t*
- Aminoglycosides, 579
- Aminolevulinic acid (ALA)

- dehydratase deficiency, 379–380
 - tests for, 382–383
- Amiodarone induced thyroid disease, 453–454
- Ammonia, 231–232
 - in acid-base balance, 523
 - analysis of, 231
 - biochemistry of, 231
 - disease correlations, 231, 486
 - interfering substances, 231–232
 - in liver failure, 486
 - in pediatric patients, 663
 - reference interval of, 232
 - sources of error in, 232
 - specimen requirements for, 231–232
- Ammonia electrode, 231
- Amniocentesis, 555
- Amniotic fluid (AF), 555–560
 - analysis of
 - for congenital diseases, 555
 - for fetal lung maturity, 557–560
 - for gestational age, 557
 - for hemolytic disease of the newborn, 555–557
 - for neural tube defects, 555
 - collection of, 555
 - processing of, 28, 29
- Amperometric-coulometric titration, 326
- Amphetamines, 599–600
- Amphipathic helices, 285–286
- Ampholyte, 105–106
- Amphoteric proteins, 188
- Amplicons, 163
- Amylase (AMS), 256–257
 - clearance, 544
 - isoenzymes, 256–257
 - in pancreatic disease, 544–545
 - and pancreatitis, 256–257
- Amyloid, 202
- Anabolic steroids, 600
- Anabolism, 637
- Analytes
 - clinical correlations of, t3–t6
 - concentration of, 3
 - defined, 7
 - performance standards for, 68t
 - reference values for, t1–t2
 - sample collection for, t3–t6
 - SI unit conversion, 676t
- Analytic performance goals, 305
- Analytic techniques, 91–120
 - chromatography, 108–115
 - electrochemistry, 101–105
 - electrophoresis, 105–107
 - osmometry, 117–119
 - for point-of-care testing, 119–120
 - for proteomics, 115–117
 - spectrophotometry and photometry, 91–101

- Analytic variations, 49
- Analytical balances, 16
- Analytical error, 70, 71
- Analytical range, 64
- Analytical run, 64, 72
- Analytical sensitivity, 64
- Analyzers, automated, 125–142 (*See also specific analyzers*)
 - basic types of, 126–127
 - chemical reaction phase in, 133–136
 - comparison of, 128*t*
 - features of, 128*t*
 - history of, 125
 - in lipid analysis, 303
 - measurement phase in, 136–138
 - in pediatric testing, 658
 - point-of-care, 83*t*
 - procedural steps in, 127, 129–139
 - reagents in, 132–133
 - selection of, 139–140
 - signal processing and data handling in, 138–139
 - specimen measurement and delivery in, 129–130, 131, 132
 - specimen preparation and identification in, 127
- Androgens, 423–424, 432
- Anemia
 - Cooley's, 390
 - in copper deficiency, 370
 - hemolytic, 620
 - iron deficiency, 197, 367–368
 - megaloblastic, 623, 624
 - pernicious, 548, 624
 - sickle cell, 385–387
 - in thalassemias, 389–390
 - in vitamin E deficiency, 620
- Angina pectoris, 497, 502
- Angiogenesis, 607
- Angiotensin, 316
- Angiotensin sensitivity test (AST), 505
- Angiotensin-converting enzyme (ACE), 415
- Anhydrous compounds, 15
- Anion gap (AG), 338–339
- Anions, 315
- Anode, 354
- Anodic stripping voltametry, 105
- Antibiotics
 - aminoglycosides, 579
 - pharmacokinetics of, 688*t*–689*t*
 - therapeutic monitoring of, 579–580
 - vancomycin, 579–580
- Antibodies
 - binding with antigens, 146–147, 148
 - and immunoglobulins, 199
 - monoclonal, 147, 611
 - in pediatric patients, 667–668
 - polyclonal, 147
 - thyroid, 449
- Anticoagulants

- in arterial blood collection, 360
 - in drug specimens, 577
 - in evacuated tubes, 27, 28*t*
 - in thrombolytic therapy, 513
- Antidiuretic hormone (ADH)
- and ACTH secretion, 418
 - deficiency of, 409
 - and osmolality, 315–316, 409
 - in pituitary function, 400, 408, 409
 - production of, 400, 409
 - in renal function, 520, 521
 - and thirst mechanism, 409, 522
- Antiepileptic drugs, 580–581
- carbamazepine, 581
 - ethosuximide, 581
 - pharmacokinetic parameters of, 688*t*
 - phenobarbital, 580
 - phenytoin, 580–581
 - valproic acid, 581
- Antigen capture assays, 155
- Antigen-antibody complexes, 146–147
- Antigens
- glycoproteins as, 193
 - in hepatitis B, 487–488, 489
 - in immunoassays, 146
- Antilogarithm, 19, 20*t*
- Antineoplastics, 583, 689*t*
- Antioxidants, 620
- Antiplatelet therapy, 513
- Antiresorptive drugs, 468
- Antithrombin III (ATT)
- cumulative frequency histogram, 51
 - frequency histograms, 49, 50, 50*t*
 - probability plot for, 59
- Antithyroglobulin autoantibodies, 449
- Anuria, 527, 532
- Aorta, coarctation of, 499
- Apoenzymes, 237
- Apolipoproteins (Apo), 285–286, 303
- Apoptosis, 605, 606, 644–645
- Arachnoid villi, 561
- ARCHITECT analyzers, 125
- Argininosuccinic aciduria, 186
- Arrhythmias, 498, 501
- Arsenic, 593
- Arterial blood, 27 (*See also* Blood gases)
- Arteries, hepatic, 476
- Arteriosclerosis, 293–294, 650
- Ascites, 566
- Ascorbic acid, 619*t*, 626
- Aspartate aminotransferase (AST), 250–251
- assay for, 250
 - diagnostic significance of, 250
 - in liver disease, 484
 - reference range for, 251
 - source of error, 251

- tissue source of, 250
- Aspiration, fine-needle, 450
- Aspirin, 597
- Assay values, 22
- Assays, duplicate, 360–361
- AST (See Aspartate aminotransferase)
- Astra Analyzer, 125, 135
- Asymmetric septal hypertrophy, 501
- α -thalassemias, 389
- Atherosclerosis, 501–502
 - in elderly, 650
 - and lipids, 283
- Atomic absorption spectrophotometry, 97–98
- Atomic weights, 684*t*–685*t*
- ATP (adenosine triphosphate), 265–266
- Atrial natriuretic peptide (ANP), 414
- Atrial septal defects (ASD), 499
- AU analyzers, 125, 128*t*
- Australia antigen, 487
- Autoanalyzer (AA), 125
- Autoantibodies, 279, 449
- Autoimmune hypoparathyroidism, 467
- Autoimmune thyroid disease, 449
- Automatic pipets, 13
- Automation, 125–142
 - analyzers in
 - basic types of, 126–127
 - history of, 125
 - selection of, 139–140, 658
 - approaches to, 126–127
 - forces towards more, 125–126
 - future trends in, 142
 - steps in analysis, 127, 129–139
 - chemical reaction phase, 133–136
 - measurement phase, 136–138
 - reagents systems and delivery, 132–133, 134
 - signal processing and data handling, 138–139
 - specimen measurement and delivery, 129–130, 131, 132
 - specimen preparation and identification, 127
 - total laboratory, 140–142
- Autosplenectomy, 387
- Auxiliary enzyme, 242
- Average deviation, 52
- Avidity of antibodies, 146, 147
- AxSYM analyzer, 136
- Azotemia, 220–221, 530

B

- B natriuretic peptide (BNP), 509, 513*t*
- β_2 -microglobulin (β_2 M)
 - characteristics of, 190*t*, 197–198
 - in renal function, 525
 - as tumor marker, 612
- Bacteria
 - detection by nucleic acid probes, 164

- Guthrie inhibition assays, 182, 184, 185
 - in urine, 527, 528, 531
- β -adrenergic blocking drugs, 512, 513*t*
- Balances, 16–17
- Bar code labels, 127, 129, 130, 139
- Barbiturates, 601
- Barometric pressure (BP), 350
- Barrier-layer cells, 94
- Bartter's syndrome, 416
- Basal metabolic rate (BMR), 629
- Base excess, 354, 358
- Bases (*See also* Acid-base balance)
 - concentrations of, 677*t*
 - defined, 344
 - pH of, 9
- Batch analysis, 126, 127
- B-cells, 667
- Beakers, Griffin, 10
- Beer's Law (BeerBouquet/Lambert), 25–26, 91–93
- Benedict's modification, 276
- Benzodiazepines, 601
- Beriberi, 622
- Beta-quantification, 302
- BH₄ (tetrahydrobiopterin), 182
- Bias, statistical, 56, 69*t*
- Bicarbonate, 326–327
 - in acid-base balance, 345, 346, 347, 348, 523
 - buffering system of, 345, 346, 348
 - calculation of, 358
 - clinical applications of, 326
 - determination of, 326–327
 - reabsorption in renal tubules, 339, 346, 347, 523
 - reference ranges of, 327
 - regulation of, 26, 523
- Bile, 477
- Bile acids, 477, 484
- Biliary tract obstruction, 252, 255
- Bilirubin
 - in amniotic fluid, 556
 - conjugated, 360, 478, 482
 - direct/indirect, 482
 - formation of, 477–478
 - frequency histogram of, 60
 - measurement of, 481–483
 - classical methods, 481–482
 - direct spectrophotometric method, 483
 - Jendrassik-Grof method, 482–483
 - method selection in, 482
 - metabolism of, 478
 - in pediatric patients, 663
 - reference ranges of, 483*t*
 - unconjugated, 482
 - in urine, 528
- Biohazard hoods, 36
- Biohazardous waste, 45
- Biologic safety, 38–39

- Biosafety hoods (cabinets), 36, 38*t*
- Biosensors, 119–120, 142
- Biotin, 625–626
- Bisalbuminemia, 194
- Bisphosphonates, 468, 469, 472
- Biuret method, 205, 212
- Blood
 - arterial, 27
 - in cerebrospinal fluid, 561
 - collection of, 26–28, 69, 657
 - regulation of volume, 315, 316–317
 - in urine, 528
 - whole, 27
- Blood gases, 344–361
 - acid-base balance in, 344–349
 - measurement of
 - analyzers in, 354
 - calculated parameters, 358
 - calibration in, 357–358
 - electrochemical sensors in, 356–357
 - optical sensors in, 357
 - pH and PCO₂, 356
 - PO₂, 354–355
 - spectrophotometric, 353–354
 - temperature correction in, 358
 - oxygen and gas exchange in, 349–353
 - in pediatric patients, 659
 - point-of-care testing for, 175
 - quality assurance in, 358–361
 - reference ranges of, 348*t*
 - specimen for, 27
- Blood glucose monitoring, 119
- Blood pressure (*See* Hypertension)
- Blood urea nitrogen (BUN), 220 (*See also* Urea)
- Bloodborne pathogens, 38–39
- Blow-out pipets, 11
- B-lymphocytes, 667
- BNP (B natriuretic peptide), 509, 513*t*
- Body cell mass, 633
- Body composition, 632–633
- Body fluids (*See* Fluids)
- Body mass index (BMI), 618
- Body surface area, 680
- Boiling point, 7
- Bond specificity, 239
- Bonds, 147, 187
- Bone
 - and calcium metabolism, 462, 663
 - cortical, 462
 - in pediatric patients, 663
 - trabecular, 462
 - and vitamin D, 460, 663
- Bone disorders
 - and acid phosphatase, 254
 - and alkaline phosphatase, 252

- cancer, 532
 - in hypercalcemia, 463
 - osteomalacia, 469–470, 524, 622
 - osteoporosis, 470–472
 - Paget's disease, 252
 - rickets, 469–470, 618, 622
 - Bone mineral densitometry, 471
 - Bone resorption, 331
 - Bone turnover, 462
 - Bowman's capsule, 518, 519
 - Brain-type natriuretic peptide (BNP), 509, 513*t*
 - Branched DNA (bDNA) assays, 164
 - Breaker-mixers, 134–135
 - Breasts
 - cancer of, 608, 613
 - development of, 434
 - Broad casts, 529
 - Bromocresol purple (BCP), 206–207
 - Bromocresol green (BCG), 206, 207
 - Bronchodilators, 582, 688*t*
 - Bruton's disease, 668
 - β -thalassemias, 389–390
 - Buffer systems (*See also* Blood gases)
 - bicarbonate-carbonic acid, 345, 346, 348
 - phosphate, 345
 - in regulation of hydrogen ion, 344–345
 - Buffers
 - defined, 8, 344
 - for electrophoresis, 105–106
 - in solutions, 8
 - Bulbs, pipet, 12
 - BUN (Blood urea nitrogen), 220 (*See also* Urea)
 - Burets, 11*t*, 15
 - Burners, pre-mix long-path, 97
- C**
- CA 15-3, 613
 - CA 19-9, 613
 - CA 125, 612
 - CA (carbonic anhydrase) isoenzyme III, 510, 513*t*
 - Cabinets, safety, 36, 38*t*
 - Cadmium, 593–594
 - Calcimimetics, 469
 - Calcitonin, 331, 446
 - Calcium, 331–334
 - determination of, 334, 335, 462
 - distribution of, 331–332
 - drugs that effect metabolism of, 468–469
 - homeostasis of, 331, 332, 458–469, 523
 - hormonal control of, 458–461
 - hypercalcemia, 333–334, 462–465, 663–664
 - hypocalcemia, 332–333, 465–468, 663–664
 - ionized, 462
 - organ systems in control of, 458, 461–462
 - and parathyroid hormone, 460–461
 - in pediatric patients, 333, 663–664

- physiology of, 331
 - reabsorption in renal tubules, 339, 523
 - reference ranges of, 334, 335*t*
 - specimens for, 334
 - in surgery and intensive care patients, 333
 - and total parenteral nutrition, 637
 - and vitamin D, 458–460
- Calcium channel antagonists, 512, 513*t*
- Calcium-sensing receptor, 460, 461
- Calculations
- concentration, 20–23
 - dilutions, 23–25
 - logarithms, 19–20
 - one point, 25
 - significant figures, 19
 - unit conversions, 675*t*
 - water of hydration, 25–26
- Calculi, renal, 186, 531
- Calibration
- of automated analyzers, 138–139
 - of balances, 17
 - of blood gas analyzers, 357–358
 - materials for, 70
 - one point, 25
 - of pH meters, 103
 - of pipets, 14–15
 - for point-of-care testing, 174
 - of thermometers, 9
- Calibration curves, 93
- Calorimetry, indirect, 618
- Cancer (*See also* Tumor markers)
- adhesion molecules in, 607
 - angiogenesis in, 607
 - apoptosis in, 606
 - benign and malignant tumors in, 605
 - breast, 608, 613
 - cancer vs. normal cells, 605
 - cell cycle in, 606
 - cell growth regulation in, 605
 - defined, 605
 - detection of recurrence, 609
 - determining prognosis, 609
 - early detection of, 609
 - gastric, 613
 - gastrinomas, 540
 - gastrointestinal, 613
 - hepatocellular, 480–481, 608, 612
 - hypercalcemia in, 464–465
 - insulinoma, 273–274
 - liver, 480–481, 608, 612
 - metastasis in, 605
 - monitoring treatment of, 608–609
 - neoplasia and hyperplasia in, 605
 - ovarian, 608, 612
 - pancreatic, 274, 540, 613
 - pheochromocytomas, 424, 426, 428

- prostate, 61, 62–63, 64, 254, 608, 614
 - signal transduction pathway in, 605, 606
- thyroid, 453, 454
- Cancer antigen 15-3 (CA 15-3), 613
- Cancer antigen 19-9 (CA 19-9), 613
- Cancer antigen 125 (CA125), 612
- Cannabinoids, 600
- CAP (See College of American Pathologists)
- Capillary electrophoresis (CE), 107, 142, 210–211
- Capillary samples, 657
- Captopril suppression, 417
- Caraway method, 229
- Carbamazepine, 581
- Carbohydrates, 263–279
 - chemical properties of, 264–265
 - classification of, 263–264
 - defined, 263
 - hyperglycemia, 268–273
 - hypoglycemia, 273–274
 - laboratory tests for, 274–279
 - glucose measurements, 275–277
 - glycosylated hemoglobin, 277–278
 - insulin, 279
 - islet autoantibody, 279
 - ketones, 278–279
 - microalbuminuria, 279, 526
 - metabolism of, 265–268, 274
 - genetic defects in, 274
 - pathways in, 265–267
 - in pediatric patients, 661–662
 - regulation of, 267–268
 - mono-, di-, and polysaccharides, 264
 - stereoisomers, 264
 - synthesis and metabolism in liver, 479
- Carbon dioxide (See also Bicarbonate)
 - in acid-base balance, 345, 346, 348
 - clinical applications of, 326
 - determination of, 326–327
 - in gas exchange, 349–351
 - measurement of, 356
 - partial pressure of (PCO₂), 354, 356
 - reference ranges of, 326
 - regulation of, 326
 - total content of, 358
- Carbon monoxide, 592–593
- Carbonic acid, 345, 358
- Carbonic anhydrase (CA) isoenzyme III, 510, 513*t*
- Carboxyhemoglobin (COHb), 352, 353, 592–593
- Carcinoembryonic antigen (CEA), 611, 613
- Carcinoembryonic proteins, 610–611
- Carcinogenic chemicals, 41
- Carcinomas (See Cancer)
- Carcinoplacental alkaline phosphatases, 253
- Cardiac function (See Heart disease)
- Cardiac glycosides, 512, 513*t*, 577–578
- Cardiac markers, 505–510

- B natriuretic peptide, 509, 513*t*
- carbonic anhydrase isoenzyme III, 510, 513*t*
- in diagnosing heart disease, 497, 506
- enzymes, 505–506
- features of, 505
- glycogen phosphorylase isoenzyme BB, 510, 513*t*
- heart fatty acid-binding protein, 510, 513*t*
- homocysteine, 185–186, 510, 513*t*
- inflammation and coagulation markers as, 507–509, 513*t*
- ischemia modified albumin, 510, 513*t*
- POC testing for, 510–511
- proteins, 506–507
- significance of, 513*t*
- troponins, 200–201, 246, 507
- Cardioactive drugs, 577–579
 - digoxin, 577–578
 - disopyramide, 579
 - lidocaine, 587
 - pharmacokinetics of, 688*t*
 - procainamide, 578–579
 - quinidine, 578
- Cardiomyopathies, 501
- Cardiovascular disease (CVD), 419 (*See also* Heart disease)
- Carnitine, 626
- Carotenoids, 551, 620
- Carryover in automated analyzers, 127, 130
- Caspases, 644
- Catabolism of proteins, 192, 629
- Catalytic mechanism of enzymes, 238–239
- Catechol methyltransferase (COMT), 425
- Catecholamines
 - biosynthesis and storage of, 424–426
 - degradation of, 424–425
 - epinephrine, 267, 424, 425
 - norepinephrine, 424, 425
 - in pheochromocytoma, 426, 428
 - urine and plasma levels of, 425
- Cathode, 95, 354
- Cation-exchange resins, 231
- Cations, 315
- Caustic agents, 593
- CCK (cholecystokinin), 540, 542
- CDC Cholesterol Reference Method Laboratory Network, 305
- CE (capillary electrophoresis), 107, 142, 210–211
- CEA (carcinoembryonic antigen), 611, 613
- Cecum, 549
- CEDIA (cloned enzyme donor immunoassays), 157
- Cells
 - cancer vs. normal, 605
 - growth of, 605
 - life cycle of, 605–606, 607
 - in urinalysis, 528
- Cellular breakdown, 322, 324
- Cellular casts, 529
- Cellulose acetate electrophoresis, 106, 392
- Centers for Medicare and Medicaid Services (CMS), 169, 171*t*

- Central nervous system disorders
 - and creatine kinase, 244
 - in hypercalcemia, 463
 - in hypocalcemia, 466
- Central nervous system-specific acetylcholinesterase (CNS-AChE), 555
- Centrifugal analyzers
 - basics of, 127
 - calibration of, 139
 - history of, 125
 - loading carousel in, 129, 130
 - measurement phase in, 137
 - mixing in, 134
 - rotor in, 129
- Centrifugation, 17–18
 - of blood specimens, 27
 - centrifugal force nomograph, 681
 - of cerebrospinal fluid, 28
 - hazards of, 44
 - in lipoprotein analysis, 300, 302
 - speed and time adjustment, 682
- CEP (congenital erythropoietic porphyria), 379, 380
- Cerebrospinal fluid (CSF)
 - analysis of, 561–563
 - blood and hemoglobin in, 561
 - collecting, 561
 - functions of, 560–561
 - glucose in, 28–29, 561–562
 - glutamine in, 486, 561
 - lactate dehydrogenase in, 561
 - processing of, 28–29
 - proteins in, 28–29, 214–215, 562–563
 - volume of, 561
- Cerebrovascular disease (CVD), 293
- Certification of staff, 174
- Certified reference material (CRM/SRM), 5
- Ceruloplasmin, 190*t*, 196, 369, 370
- Chain of custody, 31
- Chains
 - in hemoglobin, 383–384
 - immunoglobulin, 199
 - polypeptide, 187–188
- Channels of analyzers, 125
- Character in logarithm, 16
- Charge of proteins and amino acids, 188–189
- CHD (See Coronary heart disease)
- Chelators, 368
- Chem1 analyzer
 - chemical reaction phase in, 134
 - flow-through cuvet in, 136, 137
 - history of, 125, 127
- Chemical hygiene plan, 40
- Chemical reactions in analyzers, 133–136
 - incubation in, 135
 - mixing in, 134–135
 - reaction time in, 135–136
 - separation in, 135

- in total automated systems, 141
- Chemicals
 - carcinogenic, 41
 - corrosive, 41
 - disposal of, 44–45
 - flammable/combustible, 40–41
 - grades of purity, 4–5
 - hazardous, 40
 - incompatible, 678*t*–679*t*
 - labeling of, 36, 37
 - reactive, 41
 - safety with, 39–41
 - spills of, 41
 - storage of, 36–37, 40–41
 - toxic effects from, 40
- Chemiluminescence
 - in automated analysis, 138
 - in immunoassays, 151*t*, 152–153
 - in nitrogen analysis, 204
 - principles of, 100
- Chemotherapy, 228
- Children (See Pediatric patients)
- Chip technology, 142
- Chloride, 324–326
 - determination of, 325–326
 - hyperchloremia, 325, 637, 638*t*
 - hypochloremia, 325
 - reabsorption in renal tubules, 339
 - reference ranges of, 325*t*
 - regulation by kidneys, 522
 - in sweat, 544, 563, 564, 669
 - and total parenteral nutrition, 637
- Chloride shift, 325, 345
- Chloridometers, 105
- Cholecalciferol, 621
- Cholecystokinin (CCK), 540, 542
- Cholesterol
 - absorption of, 288
 - analytic performance goals for, 292*t*
 - and arteriosclerosis, 294
 - chemistry of, 284, 285
 - in elderly, 650
 - function of, 283
 - HDL cholesterol, 292*t*, 300–302
 - and heart disease, 291, 502
 - hypercholesterolemia, 289, 294, 295
 - LDL cholesterol, 292*t*, 302
 - measurement of, 298–299
 - reverse transport pathway, 288, 289–290
 - in steroid hormone biosynthesis, 414, 415
- Cholesterol Reference Method Laboratory Network, 305
- Chromatogram, 111, 112
- Chromatography, 108–115
 - adsorption, 108
 - affinity, 277
 - in amino acid analysis, 186

- automated column, 135
 - cation exchange, 278
 - defined, 108
 - gas, 111–115
 - gel permeation, 108
 - high-performance liquid, 110–111
 - ion exchange, 109
 - liquid-liquid, 108
 - liquid-solid, 108
 - modes of separation, 108–109
 - partition, 108
 - steric exclusion, 108
 - thin-layer, 109–110
 - two-dimensional, 186
- Chromium, 365*t*, 371, 638
- Chromogranin A, 426, 428, 613
- Chromosomal abnormalities, 498
- Chronic hepatitis, 490–491
- Chronic renal failure, 532, 533, 533*t*
- Chvostek's sign, 466
- Chylomicrons, 286–287, 288–289
- Cinacalcet, 469
- Circadian rhythms, 400, 401–402
- Circulation, in children, 656
- Cirrhosis of the liver, 209, 210, 252, 480
- Citrate agar electrophoresis, 392
- Citrullinemia, 186
- CK (See Creatine kinase)
- CLA (chemiluminescence assay), 151*t*, 152–153
- Clarke electrodes, 354–355
- Clearance measurements, 224, 524–525
- Clinical Laboratory Improvement Amendment of 1988 (CLIA-88)
 - allowable error limits, 68
 - in automated testing, 126
 - in point-of-care testing, 169
- Clinitest reaction, 276
- Cloned enzyme donor immunoassays (CEDIA), 157
- Clonidine suppression test, 428
- Clotting times, 176
- CMS (Centers for Medicare and Medicaid Services), 169, 171*t*
- CNS-AChE (central nervous system-specific acetylcholinesterase), 555
- Coagulation, 175–176, 622
- Coarctation of the aorta, 499
- Cobalamin (vitamin B₁₂), 619*t*, 624–625
- Cobalt, 365*t*, 371
- Cocaine, 600–601
- Coefficient of variation (CV), 51–52
- Coefficients, correlation, 55, 67
- Coenzymes, 237, 241
- Cofactors, 237, 241, 365
- Collagen, 193
- Collecting duct
 - anatomy of, 518, 519
 - and electrolytes, 340
 - physiology of, 521
- College of American Pathologists (CAP)

- and laboratory automation, 126
 - and laboratory safety, 35
 - and point-of-care testing, 169
 - proficiency program, 80
- Colligative properties of solutions, 7
- Colloid, 446
- Colloidal emulsoids, 189
- Columns
- for automated chromatography, 135
 - for gas chromatography, 112–113
 - for high-performance liquid chromatography, 110
- Coma, hepatic, 486
- Combined hyperlipidemia, 295
- Combined hyperlipoproteinemia, 296
- Combined systems disorder, 624
- Combustible chemicals, 40–41
- Commission of Office Laboratory Accreditation (COLA), 169
- Comparison-of-methods studies, 52, 53–55, 66–69
- Compensation, 348–349
- Competitive assays, 151, 153–154
- Competitive inhibitors, 241–242
- Complement, 190*t*, 198, 667
- Compressed gases, 36, 43–44
- Computers
- in automated analysis, 139
 - in point-of-care testing, 176
 - in total laboratory automation, 142
- Concentrated solutions, 7
- Concentration
- and absorption, 92, 93
 - of acids and bases, 677*t*
 - of enzymes, 240
 - of solutions, 7, 20–23
 - converting units in, 22–23
 - molality, 7
 - molarity, 7, 21
 - normality, 7, 21–22
 - percent solutions, 7, 20–21
 - saturation in, 7
 - specific gravity, 22
 - of substrates, 239–240
- Conductivity of solutions, 8
- Confidence-interval criteria, 68
- Congenital disorders
- adrenal hyperplasia, 415–418, 666
 - agammaglobulinemia, 668
 - erythropoietic porphyria, 379, 380
 - heart disease, 498–500
 - hypothyroidism, 446
 - using amniotic fluid to diagnose, 555
- Congestive heart failure, 500–501, 502, 509
- Conjugated bilirubin, 478, 482, 483
- Conjugated proteins, 192
- Connectivity in point-of-care testing, 176
- Constant error (CE), 68
- Constant systematic error, 54, 55

- Continuous ambulatory peritoneal dialysis (CAPD), 534
- Continuous cycling peritoneal dialysis, 534
- Continuous flow analyzers
 - basics of, 126–127
 - calibration of, 139
 - chemical reaction in, 134
 - history of, 125
 - incubation in, 135
 - measurement phase in, 136
 - probes in, 130
 - reagents in, 133
 - separation module in, 135
- Continuous-monitoring assays, 242–243
- Contraceptives, oral, 627*t*
- Contract negotiations, 173
- Control charts, 72, 77, 78*t*
- Control materials, 70–71, 360
- Control rules, 72–79
 - cumulative summation technique, 79
 - defined, 72
 - frequently used, 73*t*
 - multirule Shewhart procedure, 76, 77, 78–79
 - power function graphs, 73, 74, 76
 - violations of, 75
- Converting units, 22–23
- Convulated tubules
 - diseases of, 530
 - distal, 339, 518, 519, 520
 - proximal, 518, 519–520
- Cooley's anemia, 390
- Co-oximeters, 353–354
- Copper, 369–370
 - absorption of, 369
 - biochemical function of, 365*t*, 369
 - in ceruloplasmin, 196
 - deficiency of, 365*t*, 370
 - dietary requirements for, 369
 - excess of, 365*t*, 370
 - excretion of, 369
 - laboratory evaluation of, 370
 - reference values of, 365*t*
 - and total parenteral nutrition, 637–638
 - transport of, 369
- Coproporphyrin (COPRO), 378, 381
- Coronary artery bypass graft surgery (CABG), 514
- Coronary artery disease (CAD), 293
- Coronary heart disease (CHD), 501–503
 - in elderly, 650
 - heart failure in, 500–501
 - lipids and lipoproteins in, 283, 295, 296, 298, 502
 - presentation of, 502
 - risk factors for, 291*t*, 501–502
- Corpus luteum, 433
- Correlation coefficient (*r*), 55, 67
- Corrosive chemicals, 41
- Cortex

- adrenal, 414–424
 - kidney, 518
- Cortical bone, 462
- Corticotropin-releasing hormone (CRH)
 - and ACTH secretion, 418, 665
 - CRH stimulation test, 421–422
 - secretion of, 414, 415
- Cortisol
 - in adrenal insufficiency, 418–419
 - dexamethasone suppression of, 421
 - in hypercortisolism, 419–423
 - in plasma, 420–421
 - in saliva, 421
 - synthesis of, 414, 418, 665
 - in urine, 420
- Cosyntropin, 418–419
- Cough in heart disease, 498
- Coulometric chloridometers, 105
- Countercurrent multiplier system, 520
- Counterimmunoelectrophoresis, 149
- Coupled enzymatic assays
 - for amylase, 257
 - for creatinine, 226
 - NAD/NADH in, 242
 - for uric acid, 229–230
- C-reactive protein (CRP)
 - in cardiac disease, 508, 513*t*
 - characteristics of, 190*t*, 198
 - in immunity, 667
 - in nutritional assessment, 636
- Creatine
 - analysis of, 227
 - biochemistry of, 223, 224
 - disease correlations of, 225
- Creatine kinase (CK), 243–248
 - assay for, 247–248
 - diagnostic significance of, 244–247
 - isoenzymes, 245–247, 506
 - CK-BB, 245–246, 506
 - CK-MB, 245, 246, 247, 506, 507
 - CK-MM, 245, 506
 - macro-CK, 247
 - mitochondrial-CK, 247
 - sources of elevation, 245*t*
 - isoforms, 506
 - in myocardial infarctions, 244, 246, 506
 - reference range of, 248
 - sources of error in, 248
 - tissue sources of, 244
- Creatinine
 - in 24-hour urine samples, 28
 - analysis of, 225–227
 - biochemistry of, 223, 224
 - disease correlations of, 223–225
 - elimination of, 521
 - interfering substances, 227

- in pediatric patients, 663
- reference interval of, 227
- sources of error in, 227
- specimen requirements of, 227, 524
- Creatinine clearance (CrCl), 28, 224, 524–525
- Creatinine/height index, 632
- CRH (See Corticotropin-releasing hormone)
- Crigler-Najjar syndrome, 478, 661
- CRM/SRM (certified reference material), 5
- Cross-reactivity, 147
- CRP (See C-reactive protein)
- Cryogenic materials, 44
- Crystal scintillation detectors, 152
- Crystals in urine, 529
- CSF (See Cerebrospinal fluid)
- Cumulative summation (cusum) technique, 79
- Cumulative-frequency histograms, 50–51, 59
- Cumulus cells, 432
- Cushing's syndrome, 419–423
 - ACTH-dependency in, 421–422
 - algorithm for workup of, 422
 - diagnosis of, 420–421, 429
 - localization procedures, 422
 - treatment of, 423
- Cusum (cumulative summation) technique, 79
- Cuvets
 - in automated analyzers, 129–130, 131, 134
 - flow-through, 136–137
 - in spectrophotometers, 94
- CV (coefficient of variation), 51–52
- Cyanide, 593
- Cyanosis, 497
- Cyclosporine, 582
- Cystatin C, 526, 663
- Cystic fibrosis (CF), 540, 669
 - sweat test for, 544, 563–564, 669
- Cystinuria, 186, 529
- Cystitis, 531
- Cytochromes, 378
- Cytokines, 629

D

- δ -aminolevulinic acid (ALA)
 - dehydratase deficiency, 379
 - tests for, 382–383
- δ -aminolevulinic acid (ALA) synthase, 276, 378–379
- Dane particle, 486
- Data management
 - in automated analysis, 138–139, 142
 - in point-of-care testing, 174, 176
 - in total laboratory automation, 142
- D-Dimer, 509, 513*t*
- De Quervain's thyroiditis, 454
- Dead space air, 351
- Death, causes of, 646*t*
- Dehydration, 202, 649

- Dehydroepiandrosterone (DHEA), 414, 423–424
- Dehydroepiandrosterone sulfate (DHEAS), 414
- 5-dehydrotestosterone (5-DHT), 423
- 5'-deiodinase, 446–447
- Deionized water, 5, 6
- DELFA (dissociation-enhanced lanthanide fluoroimmunoassays), 158
- Deliquescent substances, 16
- Delta absorbance, 26
- Delta checks, 79, 80, 360
- Delta hepatitis, 489–490
- Denaturation of proteins, 188
- Densitometers, 106, 208, 209, 210
- Density of solutions, 22
- 11-deoxycortisol (11-DOC), 419
- Deoxyhemoglobin (HHb), 352
- Deoxyribonucleic acid (See DNA)
- Derived units, 3, 4*t*
- Descriptive statistics, 49–55
 - of paired observations, 52, 53–55
 - of single observations, 49–53
- Desiccators and desiccants, 15–16
- Detection limit, 64
- Detectors, chromatography, 111, 113
- Detoxification, 480
- DEXA (dual-energy x-ray absorptiometry), 471
- Dexamethasone suppression tests, 421
- Dextrins, 256
- DFA (direct fluorescence assays), 159
- DHEA (dehydroepiandrosterone), 414, 423–424
- Diabetes insipidus (DI), 320, 409
- Diabetes mellitus, 268–273
 - and atherosclerosis, 502
 - classification of, 268–269
 - defined, 268
 - diagnostic criteria for, 271–273
 - in elderly, 647–648
 - gestational, 269, 270–271, 272–273
 - idiopathic type 1, 269
 - laboratory findings in, 269
 - L/S ratio in, 559
 - and magnesium, 328
 - maturity-onset diabetes of youth, 270
 - and microalbumin, 213, 279, 525–526, 533
 - pathophysiology of, 271
 - in pediatric patients, 662
 - proteinuria in, 213, 525–526
 - and renal failure, 532–534
 - Type 1, 269, 271, 532, 662
 - Type 2, 269–270, 271, 532, 662
- Diabetic nephropathy (DN), 648
- Diagnostic efficacy, 61–63
- Diagnostic sensitivity, 61–63
- Dialysis
 - in acute renal failure, 534–535
 - in end-stage renal disease, 535
 - as separation technique, 18–19, 135

- Diet
 - copper requirements in, 369
 - and heart disease, 291, 292*t*, 511
 - iron requirements in, 366
 - vitamins in, 459, 627
 - zinc requirements in, 370
- DIF (direct immunofluorescence), 159
- Difference plot, 53
- Diffraction gratings, 94
- Diffusion, 315
- Digestion, 549
- Digoxin, 577–578
- 1,25-dihydroxy vitamin D (1,25(OH)₂D), 458–460, 524, 621
- Dilantin, 580–581
- Dilute solutions, 7
- Dilutions, 23–25
 - serial, 24–25
 - simple, 23–24
- Dilutor/dispensers, 13, 14
- Dimension RxL analyzer
 - cuvet production and reading system, 129–130, 131
 - features of, 128*t*
 - history of, 126
- Dipeptides, 187, 188
- 2,3-Diphosphoglycerate (2,3-DPG), 353
- Diploid, 160
- Direct bilirubin, 482
- Direct effectors, 402, 403*t*
- Direct fluorescence assays (DFA), 159
- Direct immunofluorescence (DIF), 159
- Director of POCT program, 169–170
- Disaccharides, 264
- Discrete analyzers
 - basics of, 127, 128*t*
 - history of, 125
 - incubation in, 135
 - measurement in, 136–137
 - probes in, 130, 131, 132
 - reaction phase in, 133–136
 - reagents in, 132–133
 - sample measurement and delivery in, 129–130, 131, 132
 - sample preparation and identification in, 127
 - separation in, 135
 - signal processing and data handling in, 138–139
- Disease prevalence, 62, 63*t*
- Disopyramide, 579
- Dispensers, 13, 14
- Dispersion, 51, 55
- Disposal of hazardous materials, 44–45
- Dissociation constant (K_a), 8
- Dissociation-enhanced lanthanide fluoroimmunoassays (DELFLIA), 158
- Distal convoluted tubule
 - anatomy of, 518, 519
 - and electrolyte reabsorption, 339
 - physiology of, 520

- Distal RTA, 530
- Distilled water, 5, 6
- Distribution of drugs, 572, 575
- Diuretics, 513
- Diurnal rhythm
 - in Cushing's syndrome, 420–421
 - pituitary hormones in, 400, 401–402
- DNA (deoxyribonucleic acid) (*See also* Nucleic acid probes)
 - analysis by flow cytometry, 160
 - analysis of hemoglobinopathies, 393
 - analysis of thalassemias, 393
 - assay for hepatitis B, 488
 - chemistry of, 161
 - DNA index (DI), 160
 - in protein synthesis, 191
 - screening for phenylketonuria, 183
- Documentation for POCT, 174, 175
- Dopamine, 405, 406
- Dose response relationship
 - in immunoassays, 153–154, 155
 - in toxicology, 588–589
- Double diffusion immunoassays, 148–149
- Double-antibody method, 156
- Drift errors, 358
- Drugs (*See also* Therapeutic drug monitoring)
 - abused, 598–601, 690*t*–691*t*
 - amphetamines, 599–600
 - anabolic steroids, 600
 - cannabinoids, 600
 - cocaine, 600–601
 - opiates, 601
 - phencyclidine, 601
 - prevalence of, 599*t*
 - sedative hypnotics, 601
 - aldosterone suppressors, 416
 - in arteriosclerosis, 294
 - and cancer metabolism, 468–469
 - and cardiac disease, 511, 512–513
 - as cause of thyroid disease, 453–454
 - effect on analytes, 29, 31
 - in hypercalcemia, 465
 - in hyperkalemia, 324
 - in hypomagnesemia, 328
 - metabolism of, 480, 672
 - nonsteroidal anti-inflammatory drugs, 416
 - in pediatrics, 671–672
 - pharmacokinetics of, 688*t*–689*t*
 - toxicity to liver, 481
 - and vitamin metabolism, 627*t*
- Dry chemistry slides
 - calibration of, 139
 - history of, 125
 - incubation in, 135
 - mixing in, 134
 - reagents in, 133
 - separation in, 135

- signal processing and data handling in, 139
- spectrophotometry in, 137
- Dry reagents, 132–133
- Dual-energy x-ray absorptiometry (DEXA), 471
- Dubin-Johnson syndrome, 478–479
- Duchenne muscular dystrophy, 244, 246
- Duplex, 161
- Duplicate assays, 360–361
- D-xylose absorption test, 545, 550–551
- Dye binding, 205, 206–207
- Dynamic range, 64
- Dynodes, 95
- Dysbetalipoproteinemia, familial, 296
- Dyslipidemias
 - arteriosclerosis, 293–294, 650
 - combined hyperlipoproteinemia, 296
 - defined, 283
 - hypercholesterolemia, 289, 294, 295
 - hyperlipoproteinemias, 294–295
 - hypertriglyceridemia, 295–296
 - hypoalphalipoproteinemia, 296, 298
 - hypolipoproteinemia, 296
 - Lp(a) elevation, 296
- Dyspnea, 497

E

- ED₅₀, 589
- Edema, 498
- EDTA (ethylenediaminetetraacetic acid), 27, 28*t*
- Efficiency, 62, 63
- Effusions, 565
- EGFR (estimated glomerular filtration rate), 525
- Ehrlich's reagent, 484
- EIA (enzyme immunoassays), 151*t*, 152
- Elderly (*See* Geriatric patients)
- Electrical hazards, 43
- Electrochemical cell, 101, 354
- Electrochemical sensors, 356–357
- Electrochemistry, 101–105
 - anodic stripping voltametry, 105
 - coulometric chloridometers in, 105
 - enzyme electrodes in, 104–105
 - galvanic and electrolytic cells in, 101
 - gas-sensing electrodes in, 104
 - half-cells in, 101, 102*t*
 - ion-selective electrodes in, 102
 - pH electrodes in, 102–104
- Electrodes
 - ammonia, 231
 - in blood gas analyzers, 354–355
 - Clarke, 354–355
 - enzyme, 104–105
 - gas-sensing, 104
 - indicator, 102
 - ion-selective, 102–105
 - macro/microelectrode sensors, 356–357

- pH, 102–104, 356
 - reference, 102
 - Severinghaus, 356
 - transcutaneous, 355
- Electroendosmosis, 107
- Electroimmunoassay, 150
- Electrolytes, 315–340
 - and anion gap, 338–339
 - bicarbonate, 326–327
 - calcium, 331–334
 - chloride, 324–326
 - defined, 315
 - in elderly, 649
 - functions of, 315
 - lactate, 336–338
 - magnesium, 327–330
 - in pediatric patients, 660
 - phosphate, 334–336
 - potassium, 322–324
 - and renal function, 339–340, 522–523
 - sodium, 317–322
 - in sweat, 544, 563, 564
 - in total parenteral nutrition, 637, 638*t*
 - and water, 315–317
- Electrolytic cells, 101
- Electromagnetic radiation, 91
- Electronic balances, 16, 17
- Electronic quality control, 361
- Electronic thermometers, 9
- Electro-osmotic flow (EOF), 107, 211
- Electrophoresis, 105–107
 - for alkaline phosphatase, 252–253
 - buffers for, 105–106
 - capillary, 107, 142, 210–211
 - of cerebrospinal fluid, 214
 - citrate agar, 392
 - for creatine kinase, 245, 247
 - detection and quantitation in, 106
 - electroendosmosis, 107
 - free, 207
 - hemoglobin, 392
 - isoelectric focusing, 107
 - for lactate dehydrogenase, 249
 - in lipoprotein analysis, 300
 - moving-boundary, 207
 - procedures for, 105–106
 - in protein fractionation, 207–211
 - capillary, 210–211
 - high-resolution, 210
 - isoelectric focusing, 211
 - serum-protein, 207–208, 209, 210
 - sodium dodecyl sulfate-polyacrylamide gel, 159
 - support materials for, 106
 - treatment and application of sample, 106
 - two-dimensional, 116
 - of urine, 525

- zone, 105, 211
- Electrophoretogram, 105
- Electrospray (ES), 111
- Elements, periodic table, 692 (*See also* Trace elements)
- Elimination of drugs
 - constant of, 572–574
 - first-order, 572, 573
 - metabolic clearance in, 574–575
 - rate of, 572–574, 575
 - renal clearance in, 575
- ELISA (enzyme-linked immunosorbent assays), 156
- Elution, gradient, 111, 112
- Embden-Myerhof pathway, 265–266
- Emission of energy, 91, 92
- EMIT (enzyme multiplied immunoassay technique), 156–157
- Employees/Employers, 35
- Encephalopathy, 231
- Endocarditis, infectious, 504–505
- Endocrine function (*See also* Hormones)
 - of adrenal gland, 413–429
 - in elderly, 645–647
 - hypothalamus in, 400–402, 664–665
 - of pancreas, 539–540
 - of parathyroid gland, 458–461
 - in pediatric patients, 664–666
 - of pituitary, 400–409
 - of reproductive systems, 432–442
 - of thyroid gland, 446–454
- Endogenous pathway of lipids, 288, 289
- Endosmosis, 107
- Endpoint method (Mancini), 149
- End-stage renal disease (ESRD), 220, 532, 535–536
- Energy
 - activation, 238, 239
 - metabolism, in children, 661–662
 - nutritional requirements for, 618
- Enteral feeding, 635
- Enzyme electrodes, 104–105
- Enzyme immunoassays (EIA), 151*t*, 152
- Enzyme immunochemistry, 158
- Enzyme multiplied immunoassay technique (EMIT), 156–157
- Enzyme-linked immunosorbent assays (ELISA), 156
- Enzymes, 237–259
 - as cardiac markers, 505–506
 - classification of, 237–238
 - clinically significant, 243–259
 - acid phosphatase, 253–255
 - alanine aminotransferase, 251, 484
 - alkaline phosphatase, 252–253, 484
 - amylase, 256–257
 - aspartate aminotransferase, 250–251, 484
 - creatine kinase, 243–248
 - γ -glutamyltransferase, 255–256, 485
 - glucose-6-phosphate dehydrogenase, 258–259
 - lactate dehydrogenase, 248–250, 485
 - leucine aminopeptidase, 485

- lipase, 257–258
 - 5'-nucleotidase, 485
 - summary of, 244
- definitions of, 237
- in elderly, 649, 650
- in immunoassays, 152
- kinetics of, 238–243
 - calculation of, 26, 243
 - catalytic mechanism, 238–239
 - cofactors in, 241
 - enzyme concentration in, 240
 - inhibitors in, 241–242
 - measurement of, 242–243
 - measurement of enzyme mass, 243
 - pH in, 240
 - substrate concentration in, 239–240
 - temperature in, 240–241
- in liver disease, 484–485
- nomenclature of, 237–238
- in pancreatic disease, 544–545
- in pediatric patients, 663
- properties of, 237
 - as reagents, 243
 - synthesis in liver, 479–480
 - as tumor markers, 609–610
- Enzyme-substrate (ES) complex, 239
- EOF (electro-osmotic flow), 107
- EP (erythropoietic porphyria), 379, 381
- Epinephrine (EPI)
 - biosynthesis of, 414, 424, 425
 - degradation of, 425
 - in glucose regulation, 267
 - urine and plasma measurement of, 425
- Epithelial cell casts, 529
- Epithelial cells, 528
- Epitopes, 146
- Equilibrium constant (K_a), 147
- Equipment
 - for point-of-care testing, 174
 - preventative maintenance of, 70
 - safety, 36–38
- Equivalent weight, 7
- Ergocalciferol, 621
- Ergonomic hazards, 44
- Erlenmeyer flasks, 10
- Error
 - analytical, 70, 71, 358
 - in blood gas measurement, 355, 359–360
 - clerical, 70
 - criteria for evaluating, 68
 - drift, 358
 - medically allowable, 67–68
 - pre- and postanalytic, 83, 358
 - proportional, 54, 55
 - and quality assurance, 69–70
 - random

- in comparison-of methods, 54, 55, 68, 69*t*
- in control data, 70, 71, 73, 74, 76
- detecting with precision studies, 64–65
- response of control rules to, 72–79
- in sample processing, 29, 31
- standard, 44, 52–53
- systematic
 - constant, 54, 55
 - detection with control rules, 73, 74, 75–76
 - and inaccuracy, 64, 66
 - measurement of, 56
 - proportional, 54, 55
 - and single-value criteria, 68
 - in statistics, 54, 55, 70, 71
- total, 68, 69*t*
- Erythroblastosis fetalis, 555–557
- Erythrocyte transketolase (ETK), 622
- Erythrocyte zinc protoporphyrin (ZPP), 381, 383
- Erythrocytes
 - in cerebrospinal fluid, 561
 - in urine, 528
- Erythrocytic casts, 529
- Erythropoietic porphyria (EP), 379, 381
- Erythropoietin, 524
- ES (enzyme-substrate) complex, 239
- ESRD (end-stage renal disease), 220, 532, 535–536
- Essential hypertension, 511
- Essential nutrients, 619
- Essential trace elements, 365 (*See also* Trace elements)
- Estradiol, 432
- Estriol, 432
- Estrogen receptor (ER), 613
- Estrogen replacement therapy, 436, 511
- Estrogens, 432, 666
- Estrone, 432
- Ethanol
 - common indicators of abuse, 590*t*
 - effect on liver, 481
 - toxicology of, 590
- Ethosuximide, 581
- Ethylene glycol, 591
- Ethylenediaminetetraacetic acid (EDTA), 27, 28*t*
- Euestrogenic chronic anovulation, 434
- Evacuated tubes, 26, 27, 28*t*
- Evaporation, sample, 130, 657
- Excretion
 - of acids, 523
 - of bile, 477–479
 - of copper, 369
 - defined, 346
 - of iron, 366–367
 - of zinc, 370
- Exercise
 - and cardiac disease, 502, 511
 - and elderly, 652
 - and potassium regulation, 322

Exogenous pathway of lipids, 288–289
Extracellular fluid (ECF), 315
Extracellular mass, 633
Exudates, 565
Eye protective equipment, 37

F

Fahey-McKelvey method, 149
Fallot's tetralogy, 499–500
False negatives (FN), 62
False positives (FN), 62, 63
Familial benign hypocalciuric hypercalcemia (FBHH), 461, 464
Familial combined hyperlipoproteinemia (FCH), 296
Familial dysbetalipoproteinemia, 296
Familial hypercholesterolemia (FH), 294, 295
Familial hyperparathyroidism, 464
Familial triglyceridemia, 295
Family history, and atherosclerosis, 502
Fanconi's syndrome, 527
Fasting plasma glucose, 269, 272*t*
Fasting specimens, 29
Fat (*See also* Lipids)
 in body composition, 633
 failure to absorb, 541
 fecal, 543–544, 551
 synthesis in liver, 479
Fatigue in heart disease, 498
Fat-soluble vitamins, 620–622
 symptoms of deficiencies, 619*t*
 vitamin A, 620
 vitamin D, 621–622
 vitamin E, 620–621
 vitamin K, 622
Fatty acids
 analysis of, 303
 chemistry of, 283–284
 essential, 627–628
Fatty casts, 529
Fatty streaks, 293
Feces
 fat in, 543–544, 551
 proteolytic enzymes in, 545
 urobilinogen in, 484
Feedback loops, 400, 401
Female reproductive system, 432–436
 estrogen replacement therapy, 436, 511
 female pubertal development, 434
 hirsutism, 432, 435–436
 hormonal production by, 432
 hypogonadotrophic hypogonadism, 434–435
 and infertility, 434, 436*t*
 menstrual cycle, 432–433, 434
 ovaries in, 432–436
 ovulation, 433
Ferriman-Gallwey Scale, 435
Ferritin, 367*t*, 368*t*, 369

- Fetal alcohol syndrome, 498
- Fetal fibronectin (fFN), 202, 659
- Fetal hemoglobin, 384
 - acid elution stain for, 392
 - hereditary persistence of, 390
 - quantitation of, 392–393
- FETI (fluorescence excitation transfer immunoassays), 157
- Fetus
 - gestational age of, 557
 - hemolytic disease in, 555–557
 - lung maturity in, 557–560
- FIA (fluorescent immunoassay), 151*t*, 152
- Fiber optics, 136
- Fibrin split products, 198
- Fibrinogen
 - and cardiovascular disease, 502, 509, 513*t*
 - characteristics of, 190*t*, 198
- Fibrocystic disease of the pancreas (See Cystic fibrosis)
- Fibronectin, 202, 635, 659
- Filter fluorometers, 99
- Filters
 - in fluorometers, 99
 - high efficiency particulate air, 37
 - in monochromators, 94
 - for separation, 18
 - for spectrophotometer quality assurance, 96
 - for water, 5–6
- Filtration
 - as separation technique, 18
 - of water, 5–6
- Fine-needle aspiration (FNA) biopsy, 450
- Finger stick, 27, 657
- FiO₂ (fraction of inspired oxygen), 351
- Fire extinguishers, 42–43
- Fire safety, 42–43
- Fire tetrahedron, 42
- First-order elimination, 572, 573
- First-order kinetics, 239
- First-pass metabolism, 572
- Fisher projections, 263
- Fixed-time method, 242
- Flags in automated analysis, 139
- Flame ionization detectors, 113
- Flame photometry, 98
- Flammable chemicals, 40–41
- Flasks, 10, 11*t*
- Flow cytometry, 159–160
- Fluid/plasma (F/P) ratio, 565
- Fluids, 555–566
 - amniotic, 555–560
 - ascitic, 566
 - cerebrospinal fluid, 561–563
 - collection and processing of, 28–29
 - extracellular, 315
 - gastric, 548–549
 - intracellular, 315

- pancreatic, 539, 542
- pericardial, 565
- peritoneal, 565–566
- pleural, 565
- serous, 564–566
- sweat, 544, 563–564
- synovial, 564
- Fluorescence
 - in chromatography, 111
 - direct/indirect immunofluorescence, 159
 - in fluorometry, 98–100
 - in immunoassays, 152, 157–158, 159
 - polarization, 99, 157–158, 560
- Fluorescence excitation transfer immunoassays (FETI), 157
- Fluorescence polarization immunoassay (FPIA), 157–158
- Fluorescence resonance energy transfer (FRET), 163
- Fluorescent immunoassay (FIA), 151*t*, 152
- Fluoride, 371–372
- Fluorometry, 98–100
 - advantages/disadvantages of, 100
 - for branched chain amino acids, 184–185
 - instrumentation in, 99–100
 - for phenylalanine, 182
 - for porphyrins, 383
- FO₂Hb (fractional oxyhemoglobin), 352
- Foam stability index (FSI), 558
- Folates, 519*t*, 523–524
- Folin-Ciocalteu reaction, 212
- Follicles
 - of ovaries, 392
 - of thyroid, 446
- Follicle-stimulating hormone (FSH)
 - in ovulation, 433
 - in pediatric patients, 666
 - secretion of, 401
 - in testosterone control, 437
- Follicular phase of menstrual cycle, 433
- Forms, for POCT, 174
- Fosphenytoin, 581
- FPIA (fluorescence polarization immunoassay), 157–158
- Fraction of inspired oxygen (FiO₂), 351
- Fractional (percent) oxyhemoglobin (FO₂Hb), 352
- Fractionation of proteins, 205–207
 - determination of total globulins, 207
 - dye binding, 206–207
 - electrophoresis, 207–211
 - capillary, 210–211
 - high-resolution protein, 210
 - isoelectric focusing, 211
 - serum-protein, 207–208, 209, 210
 - salt fractionation, 206
- Fractures
 - fragility, 471
 - in osteomalacia, 469–470
 - in osteoporosis, 470, 471, 647

- in rickets, 469–470
- Fragility fractures, 471
- Free electrophoresis, 207
- Free radicals, 645
- Free T₃, 448, 449
- Free T₄, 448
- Freezing point, 7
- Freezing point osmometers, 118–119, 317
- Frequency histograms, 49, 50, 52, 59, 60, 62
- FRET (fluorescence resonance energy transfer), 163
- Friedewald calculation, 299, 302
- FSH (See Follicle-stimulating hormone)
- FSI (foam stability index), 558
- F-test, 55, 56, 67
- Fume hoods, 36
- F-zone, 414, 415, 418

G

- G protein, stimulatory, 461
- G-6-PD (glucose-6-phosphate dehydrogenase), 258–259, 274
- Galactorrhea, 407
- Galactosemia, 274, 661–662
- Galvanic cells, 101
- Gamma counters, 152
- Gamma emission, 152
- Gas chromatography, 111–115
 - columns for, 112–113
 - detectors for, 113
 - in drug screening, 589
 - in ethanol determinations, 592
 - gas-liquid, 111, 112
 - gas-solid, 111
 - mass spectrometry in, 113, 115
- Gases
 - compressed, 36, 43–44
 - partial pressure of, 350, 351
- Gas-sensing electrodes, 104
- Gastric acid, 548–549
- Gastric secretion, 547–549
 - analysis of, 548–549
 - pH of, 672
 - physiology and biochemistry of, 547–548
- Gastrin, 548, 549
- Gastrinomas, 540
- Gastrointestinal function, 547–551
 - calcium absorption in, 459–460, 461
 - disorders of, 463, 468
 - and drug absorption, 571–572
 - gastric secretion, 547–549
 - intestines in, 549–551
- Gaussian distributions, 49–50, 51, 52
- Gc-globulin, 190*t*, 196
- Gel
 - in electrophoresis, 106, 208, 300
 - in immune precipitation, 147–150

- Gel filtration columns, 108, 135
- Gel permeation chromatography, 108
- Gender, in atherosclerosis, 501
- GeneChips, 164
- Genes, susceptibility, 608
- Genetic diseases, 668–671
 - cystic fibrosis, 540, 544, 563–564, 669
 - diagnosis of, 164, 555, 669–671
 - large molecule diseases, 669–670
 - newborn screening for, 669, 670*t*
 - small molecule diseases, 670–671
- Genomics, 115
- Geriatric patients, 643–652
 - biochemical and physiologic changes in, 645–650
 - cardiovascular function, 650
 - diabetes and insulin resistance, 647–648
 - electrolytes, 649
 - endocrine function, 645–647
 - enzymes, 650
 - hepatic function in, 649
 - lipids, 650
 - pulmonary function, 649
 - renal function, 648–649
 - changes in analytes in, 646*t*
 - diseases and disorders associated with, 645*t*
 - impact on laboratory, 643–644
 - and laboratory results, 650–652
 - exercise and nutrition in, 652
 - preanalytical variables in, 651
 - reference intervals, 650–651
 - therapeutic drug monitoring, 651–652
 - leading causes of death in, 646*t*
 - population increase of, 643
- Geriatrics, defined, 643
- Gerontology, 643
- Gestational age of fetus, 557
- Gestational diabetes mellitus (GDM), 269, 270–271, 272–273
- GFR (See Glomerular filtration rate)
- γ -glutamyltransferase (GGT), 255–256
 - frequency histogram for, 59
 - in liver disorders, 485
 - probability plot for, 60
- GH (See Growth hormone)
- GH-RH (growth-hormone releasing hormone), 403, 665
- Gilbert syndrome, 478
- Gitelman's syndrome, 416
- Glassware, 9–15
 - burets, 11*t*, 15
 - categories of, 9
 - characteristics of, 685*t*
 - class A tolerances, 11*t*
 - cleaning, 10, 687*t*
 - hazards of, 44
 - laboratory vessels, 10
 - pipets, 10–15
 - syringes, 15

- GLC (gas-liquid chromatography), 111–113
- Glitter cells, 528
- Globin proteins, 383, 384
- Globulins, 194–199
 - α_1 -acid glycoprotein, 195
 - α_1 -antichymotrypsin, 195–196
 - α_1 -antitrypsin, 194–195
 - α_1 -fetoprotein, 195, 555, 608, 612
 - α_2 -macroglobulin, 196–197
 - β_2 -microglobulin, 197–198, 525, 612
 - ceruloplasmin, 196
 - complement, 198
 - C-reactive protein, 190*t*, 198, 636, 667
 - fibrinogen, 190*t*, 198, 509, 513*t*
 - Gc-globulin, 196
 - haptoglobin, 196
 - hemopexin, 197
 - immunoglobulins, 198–199
 - inter- α -trypsin inhibitor, 196
 - lipoproteins, 197
 - in liver disease, 485
 - total, 207
 - transferrin, 197, 634
- Glomerular filtration rate (GFR)
 - calculation of, 224
 - and creatinine, 224–225
 - estimated, 525
 - in pediatric patients, 660
 - in renal function, 519, 524
- Glomerular proteinuria, 212–213
- Glomerulonephritis, 529–530
- Glomerulus
 - anatomy of, 518, 519
 - diseases of, 212–213, 529–530
 - electrolytes and, 339
 - function of, 519
- Gloves, 37
- Glucagon, 267, 268*t*, 271
- Glucocorticoids, 267, 469
- Glucogenic amino acids, 180
- Gluconeogenesis, 265, 267*t*, 336, 662
- Glucose
 - 2-hour post-prandial tests, 276–277
 - in cerebrospinal fluid, 561–562
 - fasting, 269, 272*t*
 - frequency histogram of, 52
 - hyperglycemia, 268–273
 - hypoglycemia, 273–274
 - measurements of, 275–276
 - metabolism of, 265–268, 337, 661–662
 - point-of-care testing, 119, 175
 - self-monitoring, 276
 - structure of, 263, 264
 - tolerance of

- categories of, 272*t*
- in elderly, 647–648
- impaired, 269
- tests for, 272, 277
- in urine, 271, 527, 637
- Glucose oxidase, 275–276
- Glucose-6-phosphate dehydrogenase (G-6-PD), 258–259, 274
- Glucosuria, 271, 527, 637
- Glutamic-oxaloacetic transaminase (GOT), 250–251, 484–485
- Glutamic-pyruvic transaminase (GPT), 251, 484–485
- Glutamine, 486, 561
- Glycogen, 265
- Glycogen phosphorylase isoenzyme BB (GPBB), 510, 513*t*
- Glycogen storage diseases, 274, 669–670
- Glycogenesis, 266–267
- Glycogenolysis, 267
- Glycolysis, 265–266, 267*t*
- Glycoproteins, 192, 193
- Glycosylated hemoglobin (HbA_{1c}), 60, 277–278
- GnRH (gonadotropin-releasing hormone), 401, 433, 437, 666
- Goals for analytical performance, 305
- Goiters, multinodular, 453
- Gonadal function, 432–442
 - ovaries, 432–436
 - anatomy of, 432
 - and estrogen replacement therapy, 436, 511
 - female pubertal development, 434
 - hirsutism, 432, 435–436
 - hormonal production by, 432
 - hypogonadotropic hypogonadism, 434–435
 - menstrual cycle in, 432–433, 434
 - ovulation, 433
 - testes, 436–442
 - anatomy of, 436–437
 - disorders of sexual development, 438
 - hypofunction of, 438–441
 - hypogonadism, 438, 441
 - physiology of, 437–438
 - testosterone replacement therapy, 441–442
- Gonadotropin-releasing hormone (GnRH), 401, 433, 437, 666
- GOT (See Aspartate aminotransferase)
- Gout, 228
- GPBB (glycogen phosphorylase isoenzyme BB), 510, 513*t*
- GPT (See Alanine aminotransferase)
- Gradient elution, 111, 112
- Graduated cylinders, 10
- Graduated pipets, 11*t*, 12
- Granular casts, 529
- Graves' disease, 449, 451–453
- Gravimetric pipet calibration, 14–15
- Griffin beakers, 10
- Group-specific enzymes, 239
- Group-specific protein, 196
- Growth
 - of cells, 605
 - in pediatric patients, 656, 663

Growth factors (GF), 402–405, 635, 665–666
 Growth hormone (GH), 402–405
 actions of, 403–404
 deficiency of, 405, 665–666
 excess of (acromegaly), 404–405, 526
 in glucose regulation, 267
 modifiers of secretion of, 403*t*
 secretion of, 665
 testing for, 404
 Growth hormone inhibiting hormone (GH-IH), 665
 Growth-hormone releasing hormone (GHRH), 403, 665
 GSC (gas-solid chromatography), 111
 Günther's disease, 380
 Guthrie bacterial inhibition assay
 in homocystinuria, 185
 in maple syrup urine disease, 184
 in phenylketonuria, 182
 Gynecomastia, 438
 G-zone, 414, 415*f*, 416

H

Hair, pubic, 434
 Half-cells, 101, 102*t*
 Half-life, of drugs, 573, 574
 Hand-grip dynamometry, 633
 Haptens (Hp), 146–147
 Haptoglobin, 190*t*, 196
 Hashimoto's thyroiditis, 451
 HAV (hepatitis A virus), 486
 Haworth projections, 263, 264
 Hazard Communication Standard, 39
 Hazards
 biohazards, 38–39
 chemical, 39–41
 compressed gases, 43–44
 cryogenic materials, 44
 disposal of materials, 44–45
 electrical, 43
 ergonomic, 44
 fire, 42–43
 mechanical, 44
 radiation, 41–42
 regulations for, 35
 safety equipment for, 36–38
 signage and labeling of, 36, 37
 HBV (hepatitis B virus), 486–488, 489
 hCG (human chorionic gonadotropin), 613
 HCP (hereditary coproporphyrin), 379, 381
 HDL (See High-density lipoproteins)
 HDL cholesterol, 292*t*, 300–302
 Heart attacks (See Myocardial infarctions)
 Heart disease, 497–514 (See *also* Cardiac markers)
 arteriosclerosis, 293–294, 650
 atherosclerosis, 283, 501–502, 650
 and cholesterol, 291, 295, 502
 congenital, 498–500

- congestive heart failure, 500–501, 502, 509
- coronary, 501–503
 - in elderly, 650
 - heart failure in, 500–501
 - lipids and lipoproteins in, 283, 295, 296, 298, 502
 - presentation of, 502
 - risk factors for, 291 *t*, 501–502
- diagnosis of, 505–511
- and diet, 291, 292 *t*, 511
- drug treatment of, 511–513
- in elderly, 650
- hypertensive, 503–504, 511
- in hypocalcemia, 466
- infective, 504–505
- monitoring, 511
- myocardial infarctions, 503
 - and aspartate aminotransferase, 250
 - and creatine kinase, 244, 246
 - and lactate dehydrogenase, 248, 249, 505–506
 - and myoglobin, 199–200, 394, 506–507
 - and troponins, 201–202, 246, 507
- rheumatic, 504
- surgical treatment of, 514
- symptoms of, 497–498
- Heart fatty acid-binding protein (H-FABP), 510, 513 *t*
- Heart transplantation, 514
- Heating bath, 135
- Heel stick, 27, 657
- Height index, 632
- Hematology, POCT for, 176
- Heme
 - catabolism of, 477–478
 - in hemoglobin, 383, 384
 - synthesis of, 378, 379
- Hemiacetal ring, 263
- Hemochromatosis, 368
- Hemodialysis, 534
- Hemofiltration, 535
- Hemoglobin, 383–393
 - absorbance curve of, 354
 - analysis of, 390–393
 - and bicarbonate buffering system, 345
 - in cerebrospinal fluid, 561
 - degradation of, 384–385, 386
 - disease correlations with, 385–387, 389–390
 - dissociation from oxygen, 353
 - electrophoresis of, 392
 - glycosylated, 60, 277–278
 - and iron, 367
 - oxygen (binding) capacity, 352
 - and oxygen transport, 351–352
 - role in the body, 383
 - structure of, 383–384
 - synthesis of, 384–385
 - in urine, 528
- Hemoglobin A_{1c}, 60, 277–278

- Hemoglobin A₂, 384, 392
- Hemoglobin Bart's, 389
- Hemoglobin F, 384
 - acid elution stain for, 392
 - hereditary persistence of, 390
 - quantitation of, 392–393
- Hemoglobin H disease, 389
- Hemoglobinopathies
 - defined, 378, 384
 - diagnosis of, 390–393
 - hemoglobin C, 387
 - hemoglobin D, 387
 - hemoglobin E, 387
 - hemoglobin S, 385–387, 391–392
 - hemoglobin SC, 387
- Hemolysis
 - and enzyme assays, 248, 250, 253, 255
 - in sample processing, 27, 29
- Hemolytic anemia, 620
- Hemolytic disease of the newborn, 555–557
- Hemopexin, 190*t*, 197
- Hemosiderosis, 368
- Henderson-Hasselbalch equation, 8, 348
- Henle's loop
 - anatomy of, 518, 519
 - ascending limb of, 518
 - descending limb of, 518
 - and electrolytes, 340
 - physiology of, 520
- HEP (hepatoerythropoietic porphyria), 379, 381
- HEPA filters, 37
- Heparin, 360
- Hepatic artery, 476
- Hepatic coma, 486
- Hepatic function (See Liver function)
- Hepatic jaundice, 478
- Hepatitis, 486–491
 - A, 486
 - B, 486–488, 489, 491
 - C, 488–489, 491
 - chronic, 490–491
 - delta, 489–490
 - E, 490
 - electrophoretic scan in, 210
- Hepatitis BcAg (HBcAg), 488, 489
- Hepatitis BeAg (HBeAg), 488, 489
- Hepatitis BsAg (HBsAg), 487–488, 489
- Hepatitis-associated antigen (HAA), 487–488
- Hepatobiliary disorders
 - alkaline phosphatase in, 252
 - γ-glutamyltransferase in, 255
- Hepatocellular carcinoma, 480–481, 608
- Hepatoerythropoietic porphyria (HEP), 379, 381
- Hepatoma, 480–481
- Hereditary coproporphyrinemia (HCP), 379, 381
- Hereditary persistence of fetal hemoglobin (HPFH), 390

- Heterogeneous immunoassays, 155
- Hexokinase method for glucose, 275, 276
- Hexose monophosphate (HMP) shunt, 265, 266
- H-FABP (heart fatty acid-binding protein), 510, 513*t*
- High Efficiency Particulate Air (HEPA) filters, 37
- High-density lipoproteins (HDL)
 - analysis of, 300–302
 - characteristics of, 286, 287
 - function of, 283
 - heart disease and, 294
 - in reverse cholesterol transport pathway, 289–290
 - on serum protein electrophoresis, 197
- Highly complex testing, 169
- High-performance liquid chromatography (HPLC), 110–111
 - columns in, 110
 - in creatinine analysis, 226–227
 - detectors in, 111
 - for porphyrins, 383
 - pumps in, 110
 - recorders in, 111
 - sample injectors in, 110–111
 - in uric acid analysis, 230
- High-performance thin-layer chromatography (HPTLC), 109–110
- High-resolution protein electrophoresis (HRE), 210
- Hirsutism, 432, 435–436
- Histograms
 - cumulative-frequency, 50–51, 59
 - frequency, 49, 50, 52, 59, 60, 62
- Hitachi analyzers
 - history of, 125
 - mixing in, 135
 - photometer in, 136
 - sample probes in, 131, 132
 - sample racks in, 129
 - wash stations in, 134
- Hitachi Clinical Laboratory Automation System (CLAS), 141
- HIV (human immunodeficiency virus), 159
- Hoesch test, 382
- Hollow-cathode lamp, 97
- Holoenzymes, 237
- Homeostasis
 - in aging, 646
 - of calcium, 331, 332, 458–469, 523
 - of pH, 344
- Homocysteine, 185–186, 510, 513*t*
- Homocystinuria, 185–186, 529
- Homogeneous immunoassays, 155
- Homovanillic acid (HVA), 424, 613–614
- Hoods, 36
- Hook effect, 612
- Hormones
 - of adrenal glands, 414–429
 - in calcium metabolism, 331, 458–461
 - in elderly, 645–647
 - in glucose regulation, 267–268
 - growth factors, 402–405, 665–666

- and hypomagnesemia, 328
 - of hypothalamus, 402
 - of islets of Langerhans, 539
 - in ovulation, 433
 - of parathyroid, 460–461
 - in pediatric patients, 664–666
 - of pituitary gland, 400–409
 - produced by ovaries, 432
 - in renal function, 523–524
 - in testicular function, 437
 - in thyroid function, 446–448
- HPLC (See High-performance liquid chromatography)
- HPTLC (high-performance thin-layer chromatography), 109–110
- HRE (high-resolution protein electrophoresis), 210
- Hs-CRP, 508, 513*t*
- Human chorionic gonadotropin (hCG), 613
- Human immunodeficiency virus (HIV), 159
- Humoral hypercalcemia of malignancy, 465
- Hyaline casts, 529
- Hyaline membrane disease, 557
- Hybridization techniques, 161–164
 - ligase chain reaction, 163
 - Northern blot, 162
 - polymerase chain reaction, 162–163
 - Q-beta replicase system, 163
 - restriction fragment length polymorphism, 164
 - reverse transcriptase-polymerase chain reaction, 163
 - self-sustained sequence replication, 163
 - signal amplification, 163–164
 - in situ hybridization, 164
 - Southern blot, 162, 164
 - summary of, 162*t*
- Hydrates, 15
- Hydrogen ion (H⁺), 344–345 (See also pH)
- Hydrolases, 237, 238*t*, 253
- Hydrolysis, 264
- Hydrops fetalis, 389
- 17-hydroxycorticosteroid (17-OHCS), 420
- 18-hydroxycorticosterone, 417
- 21-hydroxylase deficiency, 665
- Hygroscopic compounds, 15
- Hyperaldosteronism, 416, 417
- Hyperbilirubinemia, 480
- Hypercalcemia, 333–334, 462–465
 - causes of, 332*t*, 463–465
 - and hyperparathyroidism, 333, 462
 - in pediatric patients, 663–664
 - signs and symptoms of, 334, 463
 - treatment of, 334
- Hypercalciuria, 462
- Hypercarbia, 346, 349
- Hypercarotenemia, 480
- Hyperchloremia, 325, 637, 638*t*
- Hypercholesterolemia, 289, 294, 295
- Hypercortisolism, 419–423
- Hyperglycemia, 268–273 (See also Diabetes mellitus)

- laboratory findings in, 269
- in pediatric patients, 662
- Hyperglycemic agent, 267
- Hypergonadotropic hypogonadism, 438–440
 - 5- α -reductase deficiency, 439
 - Klinefelter's syndrome, 438–439
 - myotonic dystrophy, 439–440
 - Sertoli-cell-only syndrome, 440
 - testicular feminization syndrome, 439
 - testicular injury and infection, 440
- Hyperkalemia, 323–324
 - in pediatric patients, 660, 661 *t*
 - in total parenteral nutrition, 638 *t*
- Hyperlipidemias, 502
- Hyperlipoproteinemia, 294–295, 296
- Hypermagnesemia, 329–330
- Hypermetabolic state, 629
- Hypernatremia, 320
 - manifestations and causes of, 319 *t*, 638 *t*
 - in pediatric patients, 660
- Hyperosmolality, 322
- Hyperparathyroidism
 - and hypercalcemia, 333, 463–464
 - and osteomalacia, 469–470
 - primary, 463–464, 466, 467 *t*
 - and rickets, 469–470
 - secondary, 466, 467 *t*
 - tertiary, 467–468
 - and vitamin D, 622
- Hyperphenylalaninemia, 182–183
- Hyperphosphatemia, 336
- Hyperplasia, 605
- Hyperprolactinemia, 406–407, 440
- Hyperproteinemia, 202
- Hypertension (HTN)
 - and aldosterone, 416, 429
 - defined, 503
 - in elderly, 647
 - essential, 511
 - and heart disease, 502, 503–504, 511
 - in hypercalcemia, 463
 - malignant, 504
 - in pheochromocytomas, 426
 - portal, 480
 - primary, 504
 - renal, 504, 534
 - secondary, 504
- Hypertensive heart disease, 503–504, 511
- Hyperthalamic hypogonadism, 434
- Hyperthyroidism, 449, 451, 647
- Hypertriglyceridemia, 295–296
- Hyperuricemia, 228–229
- Hyperventilation, 349
- Hypervitaminosis, 464, 620
- Hypoalbuminemia, 333
- Hypoaldosteronism, isolated, 416

- Hypoalphalipoproteinemia, 296, 298
- Hypobetalipoproteinemia, 296
- Hypocalcemia, 332–333, 465–468
 - causes of, 332–333, 466–468
 - and hypomagnesemia, 332–333
 - in neonates, 333
 - in pediatric patients, 663–664
 - signs and symptoms of, 333, 466
 - in surgery and intensive care patients, 333
 - in total parenteral nutrition, 638*t*
 - treatment of, 333
- Hypochloremia, 325
- Hypocortisolism (See Adrenal insufficiency)
- Hypogammaglobulinemia, 668
- Hypoglycemia, 273–274, 662
- Hypoglycemic agent, 267
- Hypoglycorrhachia, 562
- Hypogonadism
 - diagnosis of, 441
 - in females, 434–435
 - in males, 438, 440–441
- Hypokalemia, 322–323
 - in hyperaldosteronism, 416, 417
 - in pediatric patients, 660, 661*t*
 - in total parenteral nutrition, 637, 638*t*
- Hypolipoproteinemia, 296, 298
- Hypomagnesemia, 327–329
 - causes of, 327–328
 - and hypocalcemia, 332–333, 663–664
 - in pediatric patients, 664
 - symptoms of, 328–329
 - in total parenteral nutrition, 638*t*
 - treatment of, 329
- Hyponatremia, 318–320
 - causes of, 318–319
 - classification of, 319
 - in pediatric patients, 660
 - pseudohyponatremia, 319
 - symptoms of, 319
 - in total parenteral nutrition, 638*t*
 - treatment of, 319–320
- Hypoparathyroidism, 332, 460–461, 467
- Hypophosphatemia, 335–336, 637, 638*t*
- Hypophysiotropic hormones, 402
- Hypophysis, 400
- Hypopituitarism, 407–408
- Hypoproteinemia, 202
- Hypothalamic hypogonadism, 434
- Hypothalamic-hypophysial portal system, 400–402
- Hypothalamic-pituitary-adrenal cortex system, 665
- Hypothalamic-pituitary-thyroid axis (HPTA), 401, 448, 664–665
- Hypothalamus
 - anatomy, 400, 401
 - hormones of, 402
 - and pituitary function, 400–402
- Hypothyroidism, 450–451

- congenital, 446, 664–665
 - in elderly, 647
 - etiology of, 451
 - and iodine deficiency, 446
 - in pediatric patients, 664–665
 - primary, 664–665
 - secondary, 664–665
 - subclinical, 449
 - symptoms of, 450
 - treatment of, 451
- Hypouricemia, 229
- Hypoventilation, 349
- Hypovitaminosis, 467, 619
- Hypovolemia, 317
- Hypoxemia, 349
- Hypoxia, 336, 337
- I**
- ICON (ImmunoConcentration Assay), 158
- ICP (inductively coupled plasma), 98
- Icterus, 29, 478, 480
- Icterus index, 482
- IDDM (insulin-dependent diabetes mellitus), 269, 271, 532, 662
- Identification
- of patients, 27
 - of specimens, 127, 139
- Idiopathic galactorrhea, 407
- Idiopathic hyperaldosteronism (IHA), 417
- Idiopathic type 1 diabetes, 269
- Idiotypes, 199
- IEF (isoelectric focusing), 107, 211
- IFA (indirect immunofluorescence assays), 159
- IgA
- characteristics of, 190*t*, 199, 668*t*
 - in hepatic disorders, 486
 - in pediatric patients, 668
- IgD, 190*t*, 199, 668*t*
- IgE, 190*t*, 199, 668*t*
- IGF (insulin growth factor), 403–404, 635, 665, 666
- IGF-binding proteins, 665
- IgG
- in cerebrospinal fluid, 214–215, 562–563
 - characteristics of, 190*t*, 198, 199, 668*t*
 - in hepatic disorders, 486
 - in pediatric patients, 668
 - subclasses, 668*t*
- IgG -albumin index, 215, 562
- IgM
- characteristics of, 190*t*, 198–199, 668*t*
 - in hepatic disorders, 486
 - in pediatric patients, 668
- IIF (indirect immunofluorescence), 159
- IMA (ischemia modified albumin), 510, 513*t*
- Immobilized enzymes, 243
- Immune precipitation in gel, 147–150
- counterimmunoelectrophoresis, 149

- double diffusion (Ouchterlony), 148–149
- immuno-electrophoresis, 149–150
- methods for, 148*t*
- rocket technique, 150
- single diffusion (radial immunodiffusion), 149
- Immune system
 - acute-phase proteins in, 667
 - adaptive, 667
 - antibody production in, 667–668
 - B cells in, 667
 - complement system in, 667
 - disorders of, 668
 - innate, 667
 - natural killer cells in, 667
 - in pediatric patients, 666–668
 - phagocytes in, 667
 - skin in, 667
- Immunoassays, 146–160
 - assay design, 153–155
 - for carcinoembryonic antigen, 611
 - for CK-MB, 247
 - in digoxin analysis, 578
 - DNA analysis by flow cytometry, 160
 - for enzymes, 243
 - examples of, 156–158
 - general considerations, 146–147, 151
 - immune precipitation in gel, 147–150
 - immunoblots, 158–159
 - immunocytochemistry, 159
 - immunohistochemistry, 159
 - immunophenotyping, 159–160
 - labeled, 151–160
 - labels for, 151–153
 - rapid, 158
 - separation techniques, 155–156
 - turbidimetry and nephelometry, 150–151
 - unlabeled, 147–151
- Immunoblots, 158–159
- Immunochemical assays
 - for lipoproteins, 300
 - for prostatic ACP, 254
 - for proteins, 211
- ImmunoConcentration Assay (ICON), 158
- Immunocytochemistry, 159
- Immunodeficiencies, 668
- Immuno-electrophoresis (IEP), 149–150
- Immunofixation electrophoresis (IFE), 149, 150
- Immunofluorescence assays, 159
- Immunogen, 146
- Immunogenicity of proteins, 189, 191
- Immunoglobulins (Ig)
 - in cerebrospinal fluid, 214–215, 562–563
 - characteristics of, 190*t*, 198–199
 - in immune system, 667, 668*t*
 - in liver disorders, 485
 - in pediatric patients, 667–668

- Immunohistochemistry, 159
- Immunoinhibition, 247
- Immunologic testing for malnutrition, 632
- Immunoassays, 154–155
- Immunophenotyping, 159–160
- Immunosuppressive drugs, 582–583, 689*t*
- Impaired fasting glucose, 269, 272*t*
- Impaired glucose tolerance, 269, 272*t*
- Imprecision, 64–65
- Improvement teams, 83
- In situ hybridization, 164
- Inaccuracy, 64, 65–66
- Incidentaloma, 426, 428
- Incubation, 135
- Indicator electrodes, 102
- Indicator enzyme, 242
- Indirect bilirubin, 482
- Indirect immunofluorescence assays (IFA), 159
- Indirect immunofluorescence (IIF), 159
- Inductively coupled plasma (ICP), 98
- Infants (See Pediatric patients)
- Infections
 - in testes, 440
 - urinary tract, 531
- Infectious endocarditis, 504–505
- Infectious hepatitis, 486
- Infectious substances, 39
- Infective heart disease, 504–505
- Inferential statistics, 49, 55–56
- Infertility, 434, 436*t*
- Inflammation
 - acute-phase reactants in, 208, 209, 210
 - markers of, in AMI, 507–508
- Infundibulum, 400
- Inhibin, 437
- Inhibitors
 - in enzymatic reactions, 241–242
 - inter- α -trypsin, 190*t*, 196
- Injectors for chromatography, 110–111
- Injuries, 45–46
- Innate immune system, 667
- Instrumentation
 - for chemiluminescence, 100
 - for chromatography, 108–115
 - for electrochemistry, 101–105
 - for electrophoresis, 105–107
 - for osmometry, 117–119
 - for point-of-care testing, 119–120
 - quality control of, 70
 - for spectrophotometry and photometry, 91–101
- Insulin
 - in carbohydrate metabolism, 267, 268*t*
 - described, 267
 - in diabetes mellitus, 271, 662
 - in hypokalemia, 323
 - resistance to, 647–648

- testing for, 279
- Insulin growth factor binding proteins, 665
- Insulin-dependent diabetes mellitus (IDDM), 269, 271, 532, 662
- Insulinlike growth factors (IGF)
 - and growth hormone, 403–404, 635, 665, 666
 - in liver, 479
 - in nutritional assessment, 635
- Insulinoma, 273–274
- Integra analyzers, 128*t*
- Intensive care patients, 333
- Inter- α -trypsin inhibitor (ITI), 190*t*, 196
- Interface, 176
- Interference studies, 65–66, 67*t*
- Interfering substances
 - for ammonia, 232
 - for creatinine, 227
 - in urea analysis, 222–223
 - for uric acid, 230
- Interindividual variations, 49
- Interleukins, 636
- International units (IU), 26, 243
- Interstitial cell fluid, 315
- Intestines, 549–551
 - calcium absorption in, 459–460, 461
 - physiology of, 549
 - tests of, 550–551
- Intracellular fluid (ICF), 315
- Intraindividual variation, 49
- Intravascular extracellular fluid, 315
- Intrinsic factor, 548, 624
- Inverse logarithm, 19–20
- Iodine
 - in hypothyroidism, 446, 447
 - radioactive therapy, 452–453
- Ion exchange chromatography, 109, 247
- Ion trap mass spectrometers, 113, 114
- Ion-exchange columns
 - for aminolevulinic acid, 382–383
 - in automated analyzers, 135
 - for porphobilinogen, 382–383
- Ionic strength, 8
- Ionized calcium, 462
- Ion-selective electrodes (ISE), 102–105
 - for ammonia, 231
 - in automated analyzers, 125
 - for calcium, 104, 334, 335
 - for chloride, 105, 325
 - enzyme, 104–105
 - gas-sensing, 104
 - pH electrodes, 102–104
 - for potassium, 324
 - for sodium, 320–322
 - for total CO₂, 326
 - types of, 103–104
- Iontophoresis, 105, 544, 564
- Iron, 366–369

- absorption of, 366, 367
- biochemical functions of, 365*t*, 367
- deficiency of, 365*t*, 367–368
- dietary requirements of, 366
- distribution of, 366
- excretion of, 366
- and ferritin, 369
- laboratory evaluation of, 368
- laboratory markers in disease states, 367*t*
- overload of, 365*t*, 368
- percent saturation, 369
- reference ranges of, 365*t*, 368*t*
- in tissue damage, 368
- total iron content, 368–369
- total iron-binding capacity, 369
- and transferrin, 197, 369
- transport of, 366, 367
- Ischemia, cardiac, 501, 502–503, 650 (*See also* Heart disease)
- Ischemia modified albumin (IMA), 510, 513*t*
- ISE (*See* Ion-selective electrodes)
- Islet autoantibody, 279
- Islets of Langerhans, 267, 268, 539
- Isocratic elution, 111, 112
- Isoelectric focusing (IEF), 107, 211
- Isoelectric points (pI), 189
- Isoenzymes
 - alkaline phosphatase, 252–253
 - amylase, 256–257
 - carbonic anhydrase, 510, 513*t*
 - creatine kinase, 245–246, 506, 507
 - defined, 237
 - lactate dehydrogenase, 248–250, 506
 - as tumor markers, 609–610
- Isoforms, 237
- Isomerases, 237
- Isopropanol, 591
- Isosthenuria, 527
- Isovaleric acidemia, 184, 185
- ITI (inter- α -trypsin inhibitor), 190*t*, 196
- IU (international units), 26

- Jaffe reaction, 225–226, 227
- Jaundice
 - pediatric, 480, 482, 661
 - types and causes of, 478–479, 480
- Jendrassik-Grof bilirubin method, 482–483
- Joint Commission on Accreditation of Health Care Organizations (JCAHO), 35, 126, 169

- K**
- K_a (dissociation constant), 8
- Kallmann's syndrome, 440
- Katal, 26
- Kayser-Fleischer rings, 196, 370
- Kernicterus, 480
- Ketoacidosis, 271
- Ketogenic amino acids, 180

- Ketonemia, 278
- Ketones, 278–279
 - in diabetes mellitus, 271
 - formation in liver, 479
 - structure of, 263
 - in urine, 278, 527
- Ketose, 263
- Kidneys (See Renal function)
- Kinetic assays, 242–243
- Kinetic methods
 - Fahey-McKelvey, 149
 - Jaffe method, 225, 227
- Kinetics
 - of enzymes, 238–243
 - calculation of, 26, 243
 - catalytic mechanism, 238–239
 - cofactors in, 241
 - enzyme concentration in, 240
 - inhibitors in, 241–242
 - measurement of, 242–243
 - measurement of enzyme mass, 243
 - pH in, 240
 - as reagents, 243
 - substrate concentration in, 239–240
 - temperature in, 240–241
 - first-order, 239
 - zero-order, 239, 242
- Kjeldahl method, 204
- Klinefelter's syndrome, 438–439
- K_m (Michaelis-Menten constant), 239–240, 241
- Kodak Ektachem Analyzer, 125
- Kringles, 287
- Kupffer's cells, 477
- Kwashiorkor, 628, 630

L

- Labeled immunoassays, 151–153
 - assay design, 153–155
 - DNA analysis by flow cytometry, 160
 - examples of, 156–158
 - general considerations for, 151
 - immunoblots, 158–159
 - immunocytochemistry, 159
 - immunohistochemistry, 159
 - immunophenotyping, 159–160
 - rapid immunoassay, 158
 - separation techniques in, 155–156
- Labels
 - bar code, 127, 129, 130, 139
 - for hazards, 36, 37
 - for immunoassays
 - enzyme, 152
 - fluorescent, 152
 - luminescent, 152–153
 - radioactive, 151–152
 - summary of, 151*t*

- Laboratory information systems (LIS), 142
- Laboratory safety (*See* Safety)
- Laboratory standard, 40
- Laboratory supplies, 8–16
 - balances, 16–17
 - burets, 11*t*, 15
 - desiccators and desiccants, 15–16
 - glass and plasticware, 9–15
 - pipets, 10–15
 - syringes, 15
 - thermometers, 9
 - vessels, 10, 11*t*, 15
- Lactate, 336–338
 - biochemistry and physiology, 336, 337
 - in cerebrospinal fluid, 562
 - clinical applications of, 336
 - determinations of, 336–338
 - reference ranges of, 338*t*
 - regulation of, 336
 - specimen handling for, 336–337
- Lactate dehydrogenase (LD), 248–250
 - assay for, 250
 - in cardiac disorders, 249, 505–506
 - in cerebrospinal fluid, 561
 - diagnostic significance of, 248–250
 - flipped pattern, 249
 - isoenzymes of, 248–250, 506
 - in liver disorders, 485
 - reference ranges of, 250
 - sources of error in, 250
 - tissue sources of, 248
- Lactation, 328, 406, 407
- Lactic acidosis, 336
- Lactose tolerance test, 550
- Lamellar bodies, 560
- Lamps
 - for atomic absorption spectrophotometers, 97
 - for fluorometers, 99
 - for spectrophotometers, 93–94, 96
- Large molecule diseases, 669–670
- Laser spectrometry, 101
- Laurell technique, 150
- LCR (ligase chain reaction), 163
- LD (*See* Lactate dehydrogenase)
- LDL (*See* Low-density lipoproteins)
- LDL cholesterol, 292*t*, 302
- LDL pheresis, 295
- Lead, 594–595
- Lean body mass, 633
- Lecithins/sphingomyelins (L/S) ratio, 558, 559–560, 659
- Lesch-Nyhan syndrome, 228–229
- Leucine aminopeptidase, 485
- Leucovorin rescue, 583
- Leukemias, 159–160, 164
- Leukocyte esterase, 528
- Leukocytes, in urine, 528

- Leukocytic casts, 529
- Leydig cells, 438
- LH (See Luteinizing hormone)
- Licensure for POCT, 169
- Lidocaine, 578
- Lifestyle, and atherosclerosis, 502
- Ligase chain reaction (LCR), 163
- Ligases, 237
- Light
 - measuring in automated analysis, 136–137
 - in nephelometry, 100
 - polarized, 99, 157–158
 - sources of, 93–94, 97
 - stray, 96
 - ultraviolet, 383
- Light's criteria, 565
- Limit checks, 79
- Linear range, 64
- Linear regression analysis, 53, 54–55, 67
- Linearity, 96
- Lineweaver-Burk plots, 240, 241
- Lipase (LPS), 257–258, 544–545
- Lipid-associated sialic acid in plasma (LASA-P), 614
- Lipids, 283–306
 - absorption of, 288
 - analysis of, 298–306
 - accuracy in, 304–305
 - Cholesterol Reference Method Laboratory Network in, 305
 - compact analyzers in, 303
 - performance goals for, 292*t*, 305
 - precision in, 304
 - quality control in, 305
 - specimen collection for, 305–306
 - standardization in, 304–306
 - apolipoproteins, 285–286, 303
 - in arteriosclerosis, 293–294, 650
 - chemistry of, 283–285
 - cholesterol, 284, 285, 298–299
 - in coronary heart disease, 283, 295, 296, 298, 502
 - diseases associated with, 293–296, 298
 - distribution of, 290–291
 - in elderly, 650
 - fatty acids, 283–284, 303
 - fecal, 543–544
 - HDL cholesterol, 300–302
 - LDL cholesterol, 302
 - lipoproteins, 285–287, 300–302
 - in liver function, 479
 - metabolism of, 288–290, 479
 - phospholipids, 284–285, 303
 - reference values for, 290*t*
 - triglycerides, 284, 299–300
- Lipiduria, 530
- Lipolysis, 267
- Lipoprotein (a) (Lp(a)), 287, 296
- Lipoprotein lipase (LPL), 288, 296

- Lipoprotein Measurement Working Group, 291
- Lipoproteins, 283–306 (See *also* Lipids)
 - analysis of, 298–306, 300–303
 - accuracy in, 304–305
 - Cholesterol Reference Method Laboratory Network in, 305
 - compact analyzers in, 303
 - performance goals for, 292*t*, 305
 - precision in, 304
 - quality control in, 305
 - specimen collection for, 305–306
 - standardization in, 304–306
 - apolipoproteins in, 285–286
 - characteristics of, 286*t*
 - chylomicrons, 286–287
 - and coronary heart disease, 283, 295, 298, 502
 - defined, 190*t*, 192, 197, 283
 - diseases associated with, 293–296, 298
 - distribution in population, 290–291
 - function of, 283
 - high-density
 - analysis of, 300–302
 - characteristics of, 286, 287
 - function of, 283
 - heart disease and, 294
 - in reverse cholesterol transport pathway, 289–290
 - on serum protein electrophoresis, 197
 - hyperlipoproteinemia, 294–295
 - hypolipoproteinemia, 296, 298
 - lipoprotein (a), 287, 296
 - low-density
 - analysis of, 302
 - characteristics of, 286, 287
 - function of, 283
 - and heart disease, 294
 - pheresis to remove, 295
 - in serum protein electrophoresis, 197
 - physiology and metabolism of, 287–290
 - structure of, 285–287
 - very-low-density, 197, 283, 286*t*, 287
- Liquid junctions, 102–103
- Liquid reagents, 132
- Liquid-in-glass thermometers, 9
- Liquid-liquid chromatography, 108
- Liquid-solid chromatography, 108
- Lithium, 465, 469, 581
- Liver function
 - anatomy in, 476–477
 - assessment of, 481–491
 - bilirubin, 481–483
 - enzymes, 484–485
 - hepatic synthetic ability, 485
 - hepatitis, 486–491
 - nitrogen metabolism, 485–486
 - serum bile acids, 484
 - urobilinogen, 483–484
 - detoxification and drugs, 480, 572

- disorders of, 480–481
 - and ALT, 251, 484
 - and ammonia levels, 231
 - cancer, 608
 - cirrhosis, 480
 - drug- and alcohol-related, 481
 - electrophoretic scans in, 209, 210
 - enzymes in, 484–485
 - jaundice, 478–479, 480
 - Reye's syndrome, 481
 - tumors, 480–481
- in elderly, 649
- excretion and secretion, 477–479
- in pediatric patients, 656, 661–663
- synthetic activity, 479–480
- in vitamin storage, 479
- Lobule of liver, 476–477
- Logarithms, 19–20
- Logs for POCT, 174
- Long feedback loop, 401
- Long-incubation hepatitis, 486–488, 489
- Loop injectors, 111
- Loop of Henle
 - anatomy of, 518, 519
 - and electrolytes, 340
 - physiology of, 520
- Low-density lipoproteins (LDL)
 - analysis of, 302
 - characteristics of, 286, 287
 - function of, 283
 - and heart disease, 294
 - pheresis to remove, 295
 - in serum protein electrophoresis, 197
- Lp(a) (lipoprotein (a)), 287, 296
- LPL (lipoprotein lipase), 288, 296
- LPS (lipase), 257–258, 544–545
- L/S ratio, 558, 559–560, 659
- Lumbar puncture, 561
- Luminescent labels, 152–153
- Luminol, 152
- Luminometers, 138
- Lungs
 - in acid-base balance, 345, 346, 348
 - in elderly, 649
 - fetal maturity of, 557–560
 - partial pressure of gasses in, 351
- Luteal phase of menstrual cycle, 433
- Luteinization, 432
- Luteinizing hormone (LH), 401, 433, 437, 666
- Lyases, 237
- Lymphocytes, 160, 667
- Lymphocytic thyroiditis, 449, 451
- Lymphomas, 159–160, 164

M

- Macroamylasemia, 256

- Macro-CK, 247
- Macroelectrode sensors, 356–357
- Macronutrients, 618
- MAD (mean absolute deviation), 52
- Magnesium, 327–330
 - determination of, 330
 - hypermagnesemia, 329–330
 - and hypokalemia, 323
 - hypomagnesemia, 327–329
 - physiology of, 327
 - reabsorption in renal tubules, 339, 523
 - reference ranges of, 330^t
 - regulation of, 327, 523
 - and total parenteral nutrition, 637
- Malabsorption syndrome, 541, 550, 551
- MALDI-TOF mass spectrometry, 116–117
- Male reproductive system
 - disorders of sexual development, 438
 - hypogonadism, 441
 - and infertility, 436^t
 - testes, 436–442
 - testicular hypofunction, 438–441
 - testosterone replacement therapy, 441–442
- Malignant hypertension, 504
- Malnutrition, 628–632 (*See also* Nutritional assessment)
 - defined, 628
 - in hospital patients, 629
 - inflammatory response in, 629
 - risk for, 618, 628–632
 - risk prevention program for, 632
 - and stress hypermetabolism, 629–632
- Mancini method, 149
- Manganese, 365^t, 372
- Mantissa, 16
- Maple syrup urine disease (MSUD), 184–185
- Marasmus, 628, 630
- Marijuana, 600
- Mass spectrometers (MS)
 - in automated testing, 142
 - in gas chromatography, 113, 114, 115
 - in HPLC, 111
 - MALDI-TOF, 116–117
 - SELDI-TOF, 117, 118
- Material Safety Data Sheets (MSDS), 5, 39–40
- Mathematics (*See* Calculations)
- Matrix interactions, 305
- Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF), 116–117
- Maturity-onset diabetes of youth (MODY), 270
- Mean absolute deviation (MAD), 52
- Mean (statistical), 51, 52
- Measurement
 - in automated analysis, 136–138
 - units of, 3, 4^t
- Measuring pipets, 11^t, 12
- Mechanical hazards, 44
- Median, 51

- Median eminence, 400
- Medical waste, 45
- Medications (See Drugs)
- Medulla
 - adrenal, 424–426, 428–429
 - kidney, 518
- Megaloblastic anemia, 623, 624
- MEIA (microparticle capture enzyme immunoassays), 157
- MEN syndromes, 464
- Menkes' kinky-hair syndrome, 196, 370
- Menopause, 434–435, 646
- Menorrhagia, 434
- Menstrual cycle, 432–433, 434
- Mercury, 40, 595–596
- Mercury-vapor lamps, 96
- Metabolic acidosis
 - base excess in, 358
 - causes of, 349
 - defined, 348
 - in hyperkalemia, 324
 - in pediatric patients, 659
 - in total parenteral nutrition, 637
- Metabolic alkalosis, 348, 349, 358
- Metabolism
 - of amino acids, 180, 181
 - of bilirubin, 478
 - of carbohydrates, 265–268, 274, 661–662
 - drug clearance, 575
 - of drugs, 480, 672
 - energy, 661–662
 - of glucose, 265–268, 337, 661–662
 - of lipids, 287–290, 479
 - of nitrogen, 485–486
 - of vitamins, 626–627
- Metabolites in porphyrias, 380*t*
- Metalloenzymes, 365
- Metalloproteins, 192, 365
- Metals toxicology, 593–596
 - arsenic, 593
 - cadmium, 593–594
 - lead, 594–595
 - mercury, 595–596
- Metanephrines, 425, 426
- Metastasis, 605, 607
- Methanol, 591
- Methemoglobin (MetHb), 352, 353
- Method selection, 64–69
 - comparison of, 66–69
 - evaluation of, 64, 65
 - imprecision in, 64–65
 - inaccuracy in, 65–66
- Methotrexate, 583
- Metyrapone, 419
- MFO (mixed function oxidase) system, 574
- Micelles, 189, 288
- Michaelis-Menten constant (K_m), 239–240, 241–242

Microalbumin, 213, 279, 525–526
Microalbuminuria, 213, 279, 525–526, 533
Microammeter, 355
Microarrays, 164
Microdiffusion chambers, 231
Microelectrodes, 357
Microfluorometric assays, 182, 184–185
Microion-selective electrodes, 120
Micronutrients, 618
Microparticle capture enzyme immunoassays (MEIA), 157
Micropipets, 12, 13
Microvilli, 549
Micturition, 531
Milk-alkali syndrome, 465
Minerals, and TPN, 637, 638*t*
Mitochondrial-CK (CK-Mi), 247
Mixed function oxidase (MFO) system, 574
Mixing in automated analysis, 134–135
MLC (myosin light chains), 507
Mode, 51
Moderately complex testing, 169
MODULAR ANALYTICS system, 141
Modular analyzers, 126, 128*t*, 141
Mohr pipets, 12
Molality, 7
Molar absorptivity (ϵ), 26, 92–93
Molarity (M), 7, 21
Molecular arrays, 160, 164
Molecular testing (See Nucleic acid probes)
Molybdenum, 365*t*, 372–373
Monoamine oxidase (MAO), 425
Monochromator fluorometers, 99
Monochromators
 in automated analyzers, 136
 in fluorometry, 99
 in spectrophotometers, 93, 94, 97
Monoclonal antibodies, 147, 611
Monoclonal immunoglobulins, 199, 208, 209
Monohydrogen phosphate, 523
Monosaccharides, 264
Moving-boundary electrophoresis, 207
MSDS (Material Safety Data Sheets), 5
MSUD (maple syrup urine disease), 184–185
Mucoproteins, 192
Mucoviscidosis (See Cystic fibrosis)
Multiple endocrine neoplasia (MEN) syndromes, 464
Multiple myeloma, 464
Multiple sclerosis (MS), 214–215, 562, 563
Multiple wavelength monitoring, 142
Multirule Shewhart procedure, 76, 77, 78–79
Munchausen disease by proxy, 672
Muscles
 creatine kinase in, 244, 245
 functional tests, 633
Muscular dystrophies, 244, 246
Myelin basic proteins (MBP), 215, 563

- Myocardial infarctions (AMI), 503
 - acute phase proteins in, 507–508
 - and aspartate aminotransferase, 250
 - congestive heart failure markers in, 509
 - and coronary heart disease, 503
 - and creatine kinase, 244, 246, 506
 - diagnosis of, 505–511
 - and lactate dehydrogenase, 248, 249, 505–506
 - and myoglobin, 199–200, 394, 506–507
 - and myosin light chains, 507
 - and troponins, 201–202, 246, 507
- Myocarditis, 504
- Myoglobin
 - analysis of, 394
 - as cardiac marker, 199–200, 394, 506–507
 - clinical significance of, 394
 - in renal analysis, 525
 - structure and role in the body, 393–394
- Myosin light chains (MLC), 507
- Myotonic dystrophy, 439–440
- Myxedema, 527

- N**
- NAD/NADH
 - in enzymatic reactions, 242
 - in glucose metabolism, 265–266
 - and niacin, 623
- Nagao isoenzyme, 253
- Nanofiltration, 6
- National Cholesterol Education Program (NCEP)
 - dietary guidelines, 292*t*
 - on heart disease risk factors, 291*t*
 - performance goals, 292*t*, 305
 - treatment guidelines, 292*t*
- National Committee for Clinical Laboratory Standards (NCCLS), 5
- National Fire Protection Association (NFPA), 36
- National Institute of Standards and Technology (NIST) thermometer, 9
- Natural killer (NK) cells, 667
- Negative feedback, 401
- Negative logarithm, 19–20
- Neonates (*See* Pediatric patients)
- Neoplasia, 605
- Nephelometry, 100, 101, 150–151
- Nephrons
 - anatomy of, 518, 519
 - physiology of, 519–524
- Nephropathy, diabetic, 648
- Nephrotic syndrome, 208, 209, 530
- Nernst equation, 103, 356
- Neural tube defects (NTDs), 555
- Neurohypophysis (posterior pituitary), 400
- Neuromuscular disorders, 466
- Neuron-specific enolase (NSE), 614
- Neutrophils, 528
- Newborns (*See* Pediatric patients)
- NFPA (National Fire Protection Association), 36

- Niacin, 619*t*, 623
- Nicotinamide adenine dinucleotide (See NAD)
- NIDDM (non-insulin-dependent diabetes mellitus), 269–270, 271, 532, 662
- NIST thermometer, 9
- Nitrates, 512
- Nitrite, urinary, 527
- Nitrogen
 - balance of, 192, 635–636
 - in liver assessment, 485–486
 - non-protein, 220–232
 - ammonia, 231–232
 - creatinine/creatinine, 223–227, 521
 - elimination of, 521–522
 - urea, 220–223, 521
 - uric acid, 227–230, 522
 - in pediatric metabolism, 662–663
 - in proteins, 188
 - total, 203
- Nocturia, 498
- Nodules, thyroid, 454
- Nomenclature of enzymes, 237–238
- Noncompetitive immunoassays, 154–155
- Noncompetitive inhibitors, 241, 242
- Non-insulin dependent diabetes mellitus (NIDDM), 269–270, 271, 532, 662
- Non-protein nitrogen (NPN), 220–232
 - ammonia, 231–232
 - clinically significant compounds, 220*t*
 - creatinine/creatinine, 223–227, 521, 524
 - elimination of, 521–522
 - urea, 220–223, 521
 - uric acid, 227–230, 522
- Nonrespiratory acidosis
 - base excess in, 358
 - causes of, 349
 - defined, 348
 - in hyperkalemia, 324
 - in pediatric patients, 659
 - in total parenteral nutrition, 637
- Nonrespiratory alkalosis, 348, 349, 358
- Non-SI units, 3, 4*t*
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 416
- Norepinephrine (NE), 424, 425
- Normal ranges/values (See Reference intervals)
- Normality (N), 7, 21–22
- Northern blot, 162
- NPN (See Non-protein nitrogen)
- NSE (neuron-specific enolase), 614
- Nuclear medicine techniques, 449
- Nucleic acid probes, 160–164
 - applications of, 164
 - chemistry of, 161
 - defined, 161
 - in diagnosis of porphyrias, 383
 - hybridization techniques, 161–164
 - ligase chain reaction, 163
 - Northern blot, 162

- polymerase chain reaction, 162–163
 - Q-beta replicase system, 163
 - restriction fragment length polymorphism, 164
 - reverse transcriptase-polymerase chain reaction, 163
 - self-sustained sequence replication, 163
 - signal amplification, 163–164
 - in situ hybridization, 164
 - Southern blot, 162, 164
 - summary of, 162*t*
- overview of, 160
- Nucleoproteins, 192
- 5'-nucleotidase, 485
- Nutrients, essential, 619
- Nutritional assessment, 618–638
 - body composition in, 632–633
 - creatinine/height index in, 632
 - in elderly, 652
 - energy of fuels, 618
 - energy requirements in, 618
 - essential fatty acids in, 627–628
 - functional tests in, 633
 - immunologic testing in, 632
 - and malnutrition, 618, 628–632
 - protein markers in, 633–636
 - albumin, 634
 - C-reactive protein, 636
 - fibronectin, 635
 - ideal features of, 634*t*
 - insulin growth factor-1, 635
 - interleukins, 636
 - nitrogen balance, 635
 - retinol-binding protein, 635
 - transferrin, 634
 - transthyretin, 634–635
 - total parenteral nutrition in, 636–638
 - vitamins in, 618–627
 - weight change in, 632
- Nutritionally dependent adaptive dichotomy (NDAD), 628, 630
- Nyctalopia, 620

O

- Obesity, 648
- Obstructions
 - of biliary tract, 252, 255
 - of urinary tract, 531
- Occupational Safety and Health Act (OSHA), 5, 35, 45
- Odor of urine, 526
- OGTT (oral glucose tolerance tests), 272, 277
- 1,25(OH)₂D (1,25-dihydroxy vitamin D), 458–460, 524, 621
- 25(OH)D₃ (25-hydroxycholecalciferol), 622
- OIA (optical immunoassay)
- Oligoclonal banding, 214, 563
- Oligomenorrhea, 434
- Oligosaccharides, 264
- Oliguria, 527

- Omega fatty acids, 627–628
- One point calibration, 25
- Open-loop negative feedback loops, 401
- Ophthalmopathy, 452
- Opiates, 601
- Opsonization, 198
- Optical immunoassays (OIA), 158
- Optical sensors, 357
- Oral contraceptives, 627*t*
- Oral glucose tolerance tests (OGTT), 272, 277
- Organ development, in children, 656
- Organisms, infectious
 - detection by nucleic acid probes, 164
 - Guthrie inhibition assays, 182, 184, 185
 - in urine, 527, 528
- Organophosphates, 596
- Orosomucoid, 190*t*, 195
- OSHA (Occupational Safety and Health Act), 5, 35, 45
- Osmolal gap, 317, 591
- Osmolality
 - clinical significance of, 315–316
 - defined, 117, 315
 - determination of, 317
 - in ethanol determinations, 591
 - and hyponatremia, 319, 320
 - and potassium regulation, 322
 - reference value of, 317*t*
 - specimens for, 317
 - of urine, 320
- Osmolarity, 315
- Osmometry, 117–119, 317
- Osmotic pressure, 7
- Osteoblasts, 460
- Osteoclasts, 460
- Osteomalacia, 469–470, 524, 622
- Osteoporosis, 470–472, 646–647
- Ostwald-Folin pipets, 12–13
- Otorrhea, 562
- Ouchterlony technique, 148–149
- Ovarian carcinoma, 608, 612
- Ovaries, 432–436
 - anatomy of, 432
 - and estrogen replacement therapy, 436, 511
 - female pubertal development, 434
 - hirsutism, 432, 435–436
 - hormonal production by, 432
 - hypogonadotrophic hypogonadism, 434–435
 - menstrual cycle in, 432–433, 434
 - ovulation, 433
 - polycystic ovary syndrome, 435
 - primary ovarian failure, 434–435
- Overflow proteinuria, 213
- Ovulation, 433
- Oxidation, 354
- Oxidation-reduction potential, 8
- Oxidizing agents, 8

Oxidoreductases, 237, 238*t*, 258

Oxygen

- fraction of inspired, 351
- and gas exchange, 349–351
- and hemoglobin dissociation, 353
- partial pressure of, 350, 351, 352–353, 354–355
- patient assessment of, 352–353
- transport of, 351–352

Oxygen content, 352–353

Oxygen saturation (SO₂), 352, 353–354

Oxyhemoglobin (O₂Hb), 352, 353–354

Oxytocin, 400, 409

P

PA (plasma aldosterone), 416, 417

Paget's disease (osteitis deformans), 252

Painful thyroiditis, 454

Palpitations, 498

Pancreatic carcinoma, 274, 540, 613

Pancreatic fluid, 539, 542

Pancreatic function, 538–545

- anatomy in, 538, 539
- diseases in, 540–541
- in elderly, 647
- physiology of, 538–540
- tests of, 541–545
 - D-xylose absorption, 545
 - enzymes, 544–545
 - fecal fat, 543–544
 - radiographic, 545
 - secretin/CCK, 542
 - starch tolerance, 545
 - sweat electrolytes, 544

Pancreatitis, 540–541

- and amylase, 256–257, 544–545
- and hypertriglyceridemia, 295
- and hypocalcemia, 333
- and lipase, 258, 544–545

Pancreozymin (See Cholecystokinin)

Panel testing, 638

Panhypopituitarism, 407, 408, 665

Pantothenic acid, 626

PA:PRA ratio, 417

Paracentesis fluids, 28, 29, 566

Paramax analyzer

- bar code labels in, 129, 130, 139
- history of, 125
- mixing in, 135
- photo optical system in, 136, 137
- reaction time in, 136
- reagents in, 132, 133
- sample trays in, 129, 130
- specimen measurement and delivery in, 132

Paraproteins, 199

Parasites, 528

- Parathyroid glands, 446, 460
 - hyperparathyroidism, 463–464, 466, 467, 469–470
 - hypoparathyroidism, 332, 460–461, 467
- Parathyroid hormone (PTH)
 - in bone growth, 663
 - in calcium regulation, 331, 332, 333–334, 460–461, 523
 - in electrolyte balance, 523
 - human recombinant, 469
 - in hypercalcemia, 463–465
 - in hypocalcemia, 466–467
 - and magnesium regulation, 327, 523
- Parathyroid hormone-related protein (PTHrP), 464–465
- Partial pressure of gases, 350, 351
- Partial pressure of oxygen (PO₂), 350, 351, 352–353, 354–355
- Particle concentration fluorescence immunoassays (PCFIA), 157
- Particle enhanced turbidimetric inhibition immunoassays (PETINIA), 156
- Partition chromatography, 108
- Partition coefficient, 108
- Pasteur pipets, 13
- Pathogens
 - in biological safety, 38–39
 - detection by nucleic acid probes, 164
 - Guthrie inhibition assays, 182, 184, 185
 - in urine, 527, 528
- Pathways
 - Embden-Myerhof, 265, 266
 - endogenous cholesterol, 288, 289
 - exogenous cholesterol, 288–289
 - reverse cholesterol transport, 288, 289–290
- Patient data, average of, 79–80
- Patients
 - identification of, 27
 - preparation of, 69
 - in reference-interval studies, 57–58
- PBG (porphobilinogen), 380, 382
- PCFIA (particle concentration fluorescence immunoassays), 157
- PCO₂ electrode, 104
- PCO₂ (partial pressure of carbon dioxide), 354, 356
- PCR (polymerase chain reaction), 162–163, 164
- PCT (porphyria cutanea tarda), 379, 380–381
- PDA (photodiode array) detectors, 95, 96
- Peak drug level, 575
- Pediatric patients, 656–672
 - acid-base balance in, 659
 - analyzer choice for, 658
 - antibody production in, 667–668
 - bilirubin in, 480, 482, 483*t*
 - blood gases in, 659
 - calcium and bone metabolism in, 663–664
 - calcium in, 333
 - cholesterol in, 290–291, 295
 - circulation in, 656
 - developmental changes in, 656–657
 - diabetes in, 662
 - of diabetic mothers, 271

- drug metabolism in, 671–672
 - electrolytes in, 660–661
 - endocrine function in, 664–666
 - energy metabolism in, 661–662
 - galactosemia in, 274
 - genetic diseases in, 668–671
 - growth hormone deficiency in, 405
 - growth in, 656, 663
 - hemolytic disease of the newborn, 555–557
 - homocystinuria, 185
 - immune system in, 666–668
 - jaundice in, 480, 482, 661
 - lead toxicity in, 594, 595
 - liver function in, 656, 661–663
 - lung maturity in, 557–560
 - maple syrup urine disease in, 184–185
 - nitrogen metabolism, 662–663
 - organ development in, 656
 - phenylketonuria in, 182–183
 - phlebotomy in, 657
 - point-of-care testing for, 658
 - preanalytic concerns in, 657
 - premature, 656–657
 - renal function in, 656, 660, 663
 - respiration in, 656
 - sexual maturation in, 656, 666
 - and total parenteral nutrition, 637
 - total parenteral nutrition in, 637
 - vitamin E in, 620
 - water balance in, 660–661
- Peer review, 361
- Pellagra, 623
- Pepsin, 548
- Peptic ulcers, 548
- Peptide bonds, 187
- Peptides, structure of, 187–188
- Percent purity values, 22
- Percent saturation of iron, 367*t*, 368*t*, 369
- Percent solutions, 7, 20–21
- Percent transmittance (%T), 92, 93, 682*t*–683*t*
- Percentiles, 51, 59
- Percutaneous transluminal coronary angioplasty (PTCA), 514
- Performance improvement (PI), 175
- Performance standards
 - for common analytes, 68*t*
 - for lipid analysis, 292*t*, 305
- Pericardial fluid, 565
- Pericarditis, 505
- Periodic table, 692
- Peripheral vascular disease (PVD), 293
- Peritoneal dialysis, 534, 535
- Peritoneal fluid, 565–566
- Pernicious anemia, 548, 624
- Persistent ductus arteriosus, 499
- Personal protection, 37–38, 41
- Personnel, 169–171, 173, 174

- Pesticides, 596–597
- PETINIA (particle-enhanced turbidimetric inhibition immunoassay), 156
- pH (*See also* Blood gases)
 - in acid-base balance, 344–345, 348–349, 523
 - arterial, reference value for, 344
 - of blood plasma, 344
 - of buffered solutions, 8, 344
 - in enzymatic reactions, 240
 - of gastric fluid, 672
 - maintaining homeostasis of, 344
 - measurement of, 354, 356
 - in pediatric patients, 659
 - of urine, 527
- pH meters, 102–104
 - calibration of, 103, 358
 - combination electrode in, 103–104
 - indicator electrode in, 102
 - liquid junction in, 102–103
 - and Nernst equation, 103, 356
 - readout meter in, 103
 - reference electrodes in, 102
- Phagocytes, 667
- Pharmacokinetics
 - in pediatrics, 671–672
 - summary of, 688*t*–689*t*
 - in therapeutic drug monitoring, 575–576
- Phencyclidine (PCP), 601
- Phenobarbital, 580
- Phenylalanine, 182–183
- Phenylethanolamine N-methyltransferase (PNMT), 424, 425
- Phenylketonuria (PKU), 182–183, 669
- Phenylpyruvic acid, 183
- Phenytoin, 580–581
- Pheochromocytomas (Pheo)
 - and catecholamines, 424
 - and chromogranin A, 426, 428, 613
 - diagnosis of, 426, 428, 429
 - and homovanillic acid, 614
 - outcome and prognosis of, 428
 - treatment of, 428
- Pheresis, LDL, 295
- Phlebotomy, 26–28, 657
- Phosphate, 334–336
 - in acid-base balance, 523
 - determination of, 336
 - distribution of, 335
 - hyperphosphatemia, 336
 - hypophosphatemia, 335–336, 637, 638*t*
 - physiology of, 334–335
 - reabsorption in renal tubules, 339, 523
 - reference ranges of, 336*t*
 - regulation of, 335, 523
 - in total parenteral nutrition, 637
- Phosphate buffer system, 345
- Phosphatidyl choline (PC), 558
- Phosphatidyl glycerol (PG), 558

- Phospholipids
 - in amniotic fluid, 557–559
 - analysis of, 303
 - chemistry of, 284–285
- Photocells, 94–95
- Photodetectors, 94–96
- Photodiode array (PDA) detectors, 95, 96
- Photodiodes, 95
- Photometry (See *also* Spectrophotometry)
 - in automated analysis, 136–138
 - chemiluminescence, 100
 - flame, 98
 - fluorometry, 98–100
 - lasers in, 101
 - turbidity and nephelometry, 100, 101
- Photomultiplier (PM) tubes, 95
- Photosensitivity, 379, 380, 381
- Phototubes, 95
- Physiologic development, 656
- Physiologic hypoglycemia, 662
- PIF (prolactin-inhibitory factor), 405
- Pilocarpine nitrate iontophoresis, 544, 564, 669
- Pipets, 10–15
 - air-displacement, 13
 - automatic, 13
 - blow-out, 11
 - bulbs for, 12
 - calibration of, 14–15
 - class A tolerances, 11*t*
 - classification of, 11*t*
 - cleaning, 10
 - correct positions for, 12
 - dilutor/dispensers, 13, 14
 - dispensers, 13, 14
 - measuring or graduated, 11*t*, 12
 - micropipets, 12, 13
 - Mohr, 12
 - Ostwald-Folin, 12–13
 - Pasteur, 13
 - positive-displacement, 13
 - self-draining, 11
 - serologic, 12
 - TD and TC, 10–11
 - technique for, 11, 12
 - tips for, 13–14
 - transfer, 11*t*, 12–13
 - volumetric, 12, 13
- Pituitary function, 400–409
 - anatomy in, 400, 401
 - anterior pituitary in, 400, 401, 402–408
 - embryology in, 400
 - growth hormone in, 402–405
 - and hypogonadism, 441
 - hypophysiotropic or hypothalamic hormones in, 402
 - hypopituitarism, 407–408
 - hypothalamic-hypophysial function in, 400–402

- oxytocin in, 400, 409
- posterior pituitary in, 400, 401, 408–409
- prolactin in, 405–407
- vasopressin in, 400, 409
- Pituitary stalk, 400
- pK, defined, 344
- pK_a , 8
- PKU (phenylketonuria), 182–183, 669
- Planck's formula, 91
- Plaques, 293–294
- Plasma, 27
- Plasma aldosterone (PA), 416, 417
- Plasma gastrin, 549
- Plasma proteins, 193–199
 - albumin, 193–194, 634
 - characteristics of, 190*t*
 - globulins, 194–199
 - in nutritional assessment, 633–636
 - in plasma buffering system, 345
 - prealbumin (transthyretin), 193, 562, 634–635
- Plasma renin activity (PRA), 416, 417
- Plasticware, 9–10, 686*t* (See also Glassware)
- Pleural fluid, 565
- Plumboporphyria (PP), 379
- PO₂ electrode, 104
- PO₂ (partial pressure of oxygen), 350, 351, 352–353, 354–355
- Point-of-care testing (POCT), 169–176
 - analytical techniques for, 119–120
 - for blood gases, 175
 - for cardiac tests, 510–511
 - for chemistries, 175
 - CLIA license and regulation for, 169, 171*t*
 - for coagulation, 175–176
 - communication in, 172–174, 175
 - components for establishment of, 169*t*
 - connectivity in, 176
 - contract negotiation in, 173
 - coordinator for, 170–171
 - defined, 169
 - forms/logs for, 174
 - for glucose, 175
 - for hematology, 176
 - implementation of, 173–174
 - in lipid analysis, 303
 - for pediatric patients, 658
 - procedures/policies for, 173–174
 - proficiency testing in, 174–175
 - quality control of, 81, 83, 174, 175
 - recertification for, 174
 - requests for new testing, 172
 - selection of devices/methods, 172–173
 - standardization in, 171–172
 - structure of system, 172
 - support staff for, 169–171
 - training for, 174

- validation of, 173
- waived analytes, 169, 170*t*
- Poisons, 588
- Polarized light, 99, 157–158
- Policies, in POCT, 173–174
- Polyacrylamide gel, 106, 300
- Polyclonal antibodies, 147
- Polycystic ovary syndrome (PCOS), 435, 436
- Polydipsia, 316, 317, 319
- Polymerase chain reaction (PCR), 162–163, 164
- Polypeptides, structure of, 187–188
- Polysaccharides, 264
- Polyuria, 526
- Porphobilinogen (PBG), 380, 382
- Porphyria cutanea tarda (PCT), 379, 380–381
- Porphyrias, 378, 379–381
- Porphyrinogens, 378
- Porphyrins, 378–383
 - analysis of, 381–383
 - chemistry of, 378
 - disease correlations with, 379–381
 - role in the body, 378
 - synthesis of, 378–379
- Porphyrinurias, 381
- Portal hypertension, 480
- Portal vein, 476
- Positive-displacement pipets, 13
- Posthepatic jaundice, 479
- Postpartum thyroiditis, 454
- Post-prandial tests, 276–277
- Postrenal azotemia, 221
- Postzone, 148
- Potassium, 322–324
 - and cellular breakdown, 322
 - collection of samples for, 324
 - comparison-of-methods for, 52, 53
 - determination of, 324
 - and exercise, 322
 - hyperkalemia, 322, 323–324, 638*t*
 - and hyperosmolality, 322
 - hypokalemia, 322–323, 417, 638*t*
 - in pediatric patients, 660–661
 - reference ranges of, 325*t*
 - regulation of, 322, 339, 522
 - in total parenteral nutrition, 637
 - urinary excretion of, 417
- Power functions, 73, 74, 76
- PPM (provider-performed microscopy) testing, 168
- PRA (plasma renin activity), 416, 417
- Prealbumin (transthyretin)
 - in cerebrospinal fluid, 562
 - in nutritional assessment, 634–635
 - as plasma proteins, 190*t*, 193
- Preanalytic factors, 69–70, 651, 657
- Precipitation
 - chemical, 300, 301

- immune, 147–150
 - counterimmunoelectrophoresis, 149
 - double diffusion (Ouchterlony), 148–149
 - immunoelectrophoresis, 149–150
 - immunofixation electrophoresis, 149–150
 - methods for, 148*t*
 - rocket technique, 150
 - single diffusion (radial immunodiffusion), 149
- nonimmune, 155–156
- Precision, 64–65, 304
- Predictive value theory, 61–63, 64
- Pregnancy
 - alkaline phosphatase in, 252
 - amniotic fluid testing in, 555–560
 - α -fetoprotein in, 190*t*, 195, 555
 - gestational diabetes mellitus in, 269, 270–271, 272–273
- Pregnenolone, 414, 415
- Prehepatic jaundice, 478
- Preparative ultracentrifugation, 300
- Prerenal azotemia, 221
- Preservatives, 27, 28*t*
- Preventative maintenance, 70
- Primary amenorrhea, 434
- Primary hyperparathyroidism, 463, 466
- Primary hypertension, 504
- Primary hypoparathyroidism, 332
- Primary ovarian failure, 434
- Primary respiratory acidosis, 348, 349
- Primary respiratory alkalosis, 348, 349
- Primary standards, 5, 70
- Primidone, 580
- Prisms, 94
- PRL (See Prolactin)
- Probability of error detection (P_{ed}), 73, 74
- Probability of false rejection (P_{fr}), 73, 74
- Probability plots, 55, 56, 59, 60
- Probes
 - in automated analyzers, 130, 131, 132
 - nucleic acid
 - applications of, 164
 - chemistry of, 161
 - defined, 161
 - hybridization techniques, 161–164
 - overview of, 160
- Procainamide, 578–579
- Procedures
 - manual for, 69
 - in point-of-care testing, 173–174
- Processing of specimens, 29
- Proenzymes, 237
- Proficiency testing
 - for blood gas analysis, 361
 - error limits in, 68
 - in external quality control, 80–81, 82
 - for point-of-care testing, 174–175

- Progesterone, 432
- Progesterone receptor (PgR), 613, 614
- Prognostic inflammatory nutritional index (PINI), 633
- Prolactin (PRL), 405–407
 - hyperprolactinemia, 406
 - idiopathic galactorrhea, 407
 - prolactinoma, 406–407, 440
 - secretion of, 402
- Prolactin-inhibitory factor (PIF), 405
- Prolactinoma, 406–407
- Prooxidant, 368
- Proportional error (PE), 54, 55, 68, 69*t*
- Prostaglandins (PG), 524
- Prostate cancer, 61, 62–63, 64, 254, 608, 614
- Prostate-specific antigen (PSA)
 - frequency histograms for, 62
 - and prostate cancer, 61, 62–63, 64, 254, 608, 614
 - as tumor marker, 608, 614
- Prosthetic groups, 237, 241
- Protein-free filtrate, 220
- Protein-removal columns, 135
- Proteins, 186–215
 - abnormalities of, 202, 203
 - acute-phase
 - C-reactive protein, 190*t*, 198, 636, 667
 - fibrinogen, 190*t*, 198, 509, 513*t*
 - in immunity, 667
 - in protein electrophoresis, 209, 210
 - amino acids in synthesis of, 181*t*
 - amyloid, 202
 - analysis of, 203–211
 - catabolism of, 192
 - in cerebrospinal fluid, 28–29, 214–215, 562–563
 - charge of, 188–189
 - conjugated, 192
 - defined, 180
 - fibronectin, 202, 635, 659
 - functions of, 192–193
 - G, 374
 - immunogenicity of, 189, 191
 - isoelectric point of, 189
 - molecular size of, 186
 - myelin basic, 215, 563
 - myoglobin, 199–200, 394, 506–507, 525
 - nitrogen balance of, 192
 - nitrogen content in, 188
 - in nutritional assessment, 633–636
 - oligoclonal, 214, 563
 - plasma, 190*t*, 193–199
 - production in liver, 479, 485
 - separating in automatic analyzers, 135
 - simple, 192
 - solubility of, 189
 - structure of, 187–188
 - synthesis of, 191–192
 - troponin, 200–201, 246, 507

- urinary, 211–214
- Proteinuria, 211–214
 - analysis methods for, 211–212
 - electrophoresis of, 525
 - glomerular, 212–213
 - microalbuminuria, 213, 279, 525–526, 533
 - overflow, 213
 - significance of, 212–214
 - Tamm-Horsfall protein, 213–214
 - testing for, 527
 - tubular, 213
- Proteoglycans, 192
- Proteomics instrumentation, 115–117
 - MALDI-TOF mass spectrometry, 116–117
 - SELDI-TOF mass spectrometry, 117, 118
 - two-dimensional electrophoresis, 116
- Prothrombin time, 485, 622
- Protoporphyrin (PROTO), 378
- Provider-performed microscopy (PPM) testing, 168
- Proximal convoluted tubule
 - anatomy of, 518, 519
 - electrolytes and, 339
 - physiology of, 519–520
- Proximal RTA, 530
- Prozone, 148
- PSA (See Prostate-specific antigen)
- Pseudoaldosteronism, 416
- Pseudocholinesterase (SChE), 596–597
- Pseudohyponatremia, 319
- Pseudohypoparathyroidism, 333, 460–461, 467
- Psychoactive drugs, 581–582
 - lithium, 581
 - pharmacokinetic parameters of, 689*t*
 - tricyclic antidepressants, 581–582
- PTH (See Parathyroid hormone)
- Pubertal development, 434, 438
- Pubic hair, 434
- Pulmonary function (See Lungs)
- Pulsatile secretions, 400, 401
- Pulse oximetry (SpO₂), 352
- Pumps, 110, 133
- PV⁻ (predictive value of a negative test), 62, 63
- PV⁺ (predictive value of a positive test), 62, 63
- Pyelonephritis, 531
- Pyridoxine, 619*t*, 623
- Pyrrole rings, 378
- Pyuria, 531

Q

- Q-beta replicase system, 163
- Quadrupole mass spectrometers, 113, 114
- Quality assurance (See *also* Quality control)
 - in blood gas analysis, 358–361
 - defined, 69
 - of point-of-care testing, 81, 83

- preanalytic factors in, 69–70
 - quality patient care in, 83–84
 - of spectrophotometers, 96
- Quality control, 70–81
- for blood gas analysis, 360–361
 - control charts, 72, 77, 78*t*
 - control rules in, 72–79
 - defined, 69
 - electronic, 361
 - external, 80–81, 82
 - in lipid analysis, 305
 - materials for, 70–71
 - patient data for, 79–81
 - in point-of-care testing, 81, 83, 174, 175
 - prospective, 361
 - statistical system of, 70, 71–81
- Quality improvement (QI), 174
- Quality teams, 83
- Quaternary structure, 188, 237
- Quenching, 100
- Quinidine, 578
- R**
- RA1000 analyzer, 127, 130, 134
- Radial immunodiffusion (RID), 149
- Radiation
- disposal of waste, 45
 - electromagnetic, 91
 - nonionizing, 41–42
 - safety policies for, 41–42
- Radioactive iodine uptake (RAIU), 449–450
- Radioactive labels, 151–152
- Radioimmunoassays (RIA), 151–152, 158
- RAIU (radioactive iodine uptake), 449–450
- Random access, 125, 126
- Random error (RE)
- in comparison-of methods, 54, 55, 68, 69*t*
 - in control data, 70, 71, 73, 74, 76
 - detecting with precision studies, 64–65
- Rape investigations, 254
- Rapid immunoassays, 158
- Rate of mobility, 105
- RBP (retinol-binding protein), 635
- RDA (See Recommended dietary allowances)
- Reabsorption
- defined, 345
 - of urea, 220, 521
 - of uric acid, 227, 522
- Reaction time, 135–136
- Reactive chemicals, 41
- Readout meters, 103
- Reagents
- in automated analysis, 132–133
 - chemicals, 4–5
 - enzymes as, 243
 - monoclonal antibodies, 147, 611

- for point-of-care testing, 174
 - quality assurance of, 70
 - reference materials, 5
 - solution properties, 6–8
 - water, 5–6
- Receiver operating characteristic (ROC) curves, 63, 64
- Receptor assays, 151
- Reclamation, 346
- Recommended dietary allowances (RDA), 626
- of biotin, 626
 - of folate, 624
 - of niacin, 623
 - of pyridoxine, 623
 - of riboflavin, 623
 - of thiamine, 622
 - of vitamin A, 620
 - of vitamin B₁₂, 624
 - of vitamin D, 621
 - of vitamin E, 621
 - of vitamin K, 622
- Recorders, chromatographic, 111
- Recovery studies, 65–66
- Red blood cell casts, 529
- Red blood cells (See Erythrocytes)
- Redox potential, 8
- Reducing agents, 8
- carbohydrates as, 264–265
- 5- α -reductase deficiency, 439
- Reduction
- defined, 354
 - standard potentials of, 102*t*
- Refeeding syndrome, 629
- Reference electrodes, 102
- Reference intervals
- for analytes, t₁–t₂
 - for acid phosphatase, 255
 - for alanine aminotransferase, 251
 - for alkaline phosphatase, 253
 - for ammonia, 232
 - for amylase, 257
 - for arterial blood gases, 348*t*
 - for ascorbic acid, 626
 - for aspartate aminotransferase, 251
 - for bilirubin, 483*t*, 590*t*
 - for calcium, 334, 335*t*
 - for carbon dioxide, 327
 - for chloride, 326*t*
 - for creatine kinase, 248
 - for creatinine, 227
 - for creatinine clearance, 525
 - for fatty acids, 627*t*
 - for fecal lipids, 544
 - for γ -glutamyltransferase, 256
 - for glucose-6-phosphate dehydrogenase, 259
 - for iron, 368*t*

- for lactate, 338*t*
 - for lactate dehydrogenase, 250
 - for lipase, 258
 - for lipids, 290*t*
 - for magnesium, 330*t*
 - for osmolality, 317*t*
 - for phosphate, 336*t*
 - for plasma proteins, 190*t*
 - for point-of-care testing, 174
 - for potassium, 324*t*
 - for sodium, 322*t*
 - for urea, 223
 - for uric acid, 230
 - for urobilinogen, 484
 - for vitamin B₁₂, 625
 - for D-xylose absorption test, 551*t*
 - in children, 58
 - collection of data for, 58
 - definition of, 57–58
 - in elderly, 650–651
 - statistical analysis of, 58–61
 - validation of, 61
- Reference materials, 5
- Reference methods, 66
- Reflectance spectrophotometry, 137, 138
- Refractometry, 204–205, 527
- Regan isoenzyme, 253
- Regression analysis, 53, 54–55, 67
- Regulations, 35, 169
- Relative centrifugal force (RCF), 18
- Renal calculi, 531
- Renal failure, 531–536
- acute, 531–532, 534–535
 - and calcium metabolism, 465, 468
 - chronic, 532, 533, 533*t*
 - and diabetes mellitus, 532–534
 - end-stage, 532, 535–536
 - and hypertension, 534
 - treatment of, 534–536
 - and uremia, 220
- Renal function, 518–536
- in acid-base balance, 345, 346, 347, 348, 523
 - analysis of, 524–529
 - β₂-microglobulin, 197, 525
 - clearance measurements, 524–525
 - cystatin C, 526
 - microalbumin, 213, 279, 525–526
 - myoglobin, 525
 - urinalysis, 526–529
 - urine electrophoresis, 525
 - anatomy in, 518, 519
 - in calcium metabolism, 461–462
 - and creatinine, 223–224, 521
 - disorders of, 529–537
 - calculi, 531

- glomerular diseases, 212–213, 529–530
 - in hypercalcemia, 463
 - in hypocalcemia, 333, 463
 - obstructions, 531
 - renal failure, 531–536
 - tubular diseases, 530
 - and uric acid, 228
 - urinary tract infections, 531
 - in drug elimination, 572
 - in elderly, 648–649
 - and electrolyte balance, 322, 339–340, 522–523
 - and elimination of NPN, 220–221, 521–522
 - and endocrine function, 523–524
 - functions of, 339, 518
 - glomerular filtration in, 339, 519
 - and magnesium regulation, 327, 523
 - and parathyroid hormone, 462
 - in pediatric patients, 656, 660, 663
 - physiology in, 519–524
 - transplantation in, 535–536
 - tubular function in, 339–340, 519–521
 - in vitamin D metabolism, 461–462, 524
 - in water balance, 522
- Renal threshold, 520
- Renal tubular acidosis (RTA), 530
- Renal tubules
- anatomy of, 518, 519
 - collecting duct in, 340, 518, 519, 521
 - diseases of, 530
 - distal convoluted, 339, 518, 519, 520
 - and electrolytes, 339–340
 - function of, 519–521
 - Henle's loop in, 518, 519, 520
 - proximal convoluted, 518, 519–520
- Renin
- and aldosterone, 415
 - in blood volume regulation, 316
 - plasma renin activity, 416
 - in renal function, 523–524
- Renin-angiotensin system (RAS), 316, 415–416, 522, 523
- Reproductive system (See Gonadal function)
- Resistivity, 8
- Respirators, 37
- Respiratory acidosis, 348, 349
- Respiratory alkalosis, 348, 349
- Respiratory distress syndrome, 557, 659
- Respiratory quotient (RQ), 618
- Respiratory system
- in acid-base balance, 345, 346, 347, 348, 349
 - in elderly, 649
 - in pediatric patients, 656
- Restriction fragment length polymorphism (RFLP), 164
- Results, reporting, 175
- Ret* protooncogene, 464
- Retention factor (R_f), 109
- Retinoic acid, 620

Retinol, 620
Retinol-binding protein (RBP), 635
Reverse cholesterol transport pathway, 288, 289–290
Reverse osmosis (RO) water, 5, 6
Reverse transcriptase-polymerase chain reaction (RT-PCR), 163
Reversed-phase high performance liquid chromatography, 110
Reye's syndrome, 231, 481
RFLP (restriction fragment length polymorphism), 164
Rhabdomyolysis, 525
Rheumatic heart disease, 504
Rhinorrhea, 562
RIA (radioimmunoassays), 151–152, 158
Riboflavin, 619*t*, 622–623
Ribonucleic acid (RNA), 161, 191–192
Rickets, 469–470, 618, 622
RID (radial immunodiffusion), 149
Right to Know Law, 39
Risk assessment, 588
RNA (ribonucleic acid), 161, 191–192
RO (Reverse osmosis) water, 5
Robotics, 127, 141, 142
ROC (receiver operating characteristic) curves, 63, 64
Rocket technique, 150
Rotors for analyzers, 127, 129
Rotor's syndrome, 478
RT-PCR (reverse transcriptase-polymerase chain reaction), 163
Rubella virus, 498
Runner's amenorrhea, 434
R-zone, 414, 415

S

Safety, 35–46
 and accidents, 45–46
 awareness of, 35–36
 biologic, 38–39
 chemical, 39–41
 for compressed gases, 43–44
 for cryogenic materials, 44
 disposal of hazardous materials, 44–45
 electrical, 43
 equipment, 36–38
 ergonomic hazards, 44
 fire, 42–43
 mechanical, 44
 radiation, 41–42
 regulations for, 35
 responsibilities for, 35–35
 signage and labeling, 36, 37
Salicylates, 597
Saliva, 421
Salt
 excess ingestion of, 320
 fractionation with, 206
 salting-in/salting out, 189
Sample cells, 93, 94
Sample injectors, 110–111

- Samples (See Specimens)
- Sandwich assays, 155
- Saturated solutions, 7
- Schilling test, 624
- SCID (severe combined immune deficiency), 668
- Scintigraphy, 418
- Sclerosing panencephalitis (SSPE), 562
- Scrotal patch, 442
- Scurvy, 618, 626
- SDI (standard deviation indices), 81
- SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), 159
- Second-antibody method, 156
- Secondary amenorrhea, 434, 435*t*
- Secondary hyperparathyroidism, 466
- Secondary hypertension, 504
- Secondary porphyrias, 381
- Secondary standards, 5, 70
- Secretagogues, 547
- Secretin, 540, 542
- Secretion
 - of bilirubin, 478–479
 - of creatinine, 223
 - defined, 346
 - of thyroid hormones, 446–448
- Sedative hypnotics, 601
- Sediment, urinary, 528–529
- Segmented neutrophils, 528
- SELDI-TOF mass spectrometry, 117, 118
- Selenium, 365*t*, 373, 638
- Self-draining pipets, 11
- Self-monitoring of blood glucose (SMBG), 276
- Self-sustained sequence replication (3SR), 163
- Sella turcica, 400
- SEM (standard error of the mean), 52–53
- Sensitivity
 - analytical, 64
 - diagnostic, 61–63
 - in fluorometry, 100
 - in tumor markers, 608
- Sensors, 356–357
- Separation techniques, 17–19
 - in automated analysis, 135
 - centrifugation, 17–18
 - in chromatography, 108–109
 - dialysis, 18–19
 - filtration, 18
 - in immunoassays, 155–156
 - in lipoprotein analysis, 300
- Septal defects, 498–499
- Serial dilutions, 24–25
- Serologic pipets, 12
- Serous fluids, 564–566
 - pericardial fluid, 565
 - peritoneal fluid, 565–566
 - pleural fluid, 565
- Sertoli cells, 438, 440

- Serum, 5, 27, 30*t*
- Serum bile acids, 484
- Serum hepatitis, 486–488, 489
- Serum iron, 367*t*, 368–369
- Serum protein electrophoresis (SPE), 207–208, 209, 210
- Serum transferrin receptors, 368
- Serum-ascites albumin gradient (SAAG), 566
- Severe combined immune deficiency (SCID), 668
- Severinghaus electrode, 356
- Sexual maturation, 656, 666
- SGOT (See Aspartate aminotransferase)
- SGPT (See Alanine aminotransferase)
- Shifts
 - in quality control, 71
 - in reference ranges, 58
- Shipping biohazardous materials, 39
- Short feedback loop, 401
- Short-incubation hepatitis, 486
- SI units (Système International d'Unités), 3, 4*t*, 675*t*, 676*t*
- SIADH (syndrome of inappropriate ADH secretion), 319
- Sickle cell disease, 385–387, 391–392
- Sickling hemoglobin, 391–392
- Siderophilin (See Transferrin)
- Signage for hazards, 36, 37
- Signal amplification methods, 163–164
- Signal processing, 138–139
- Signal transduction pathway, 605, 606
- Significant figures, 19
- Simple dilutions, 23–24
- Simple proteins, 192
- Simultaneous Multiple Analyzer (SMA), 125, 127
- Single-channel analyzers, 125
- Single-diffusion immunoassays, 149
- Single-value criteria, 68, 69*t*
- Sinusoids of liver, 477
- Sitosterolemia, 288
- Skeletal disorders (See Bone disorders)
- Skewness, 50, 59
- Skin in immune system, 667
- SLFIA (substrate-level fluorescence immunoassays), 157
- Slide technology (See Dry chemistry slides)
- Small molecule diseases, 670–671
- SMBG (self-monitoring of blood glucose), 276
- Smoking
 - and cardiac disease, 502, 511
 - effect on analytes, 29, 30*t*
- SO₂ (oxygen saturation), 352, 353–354
- Sodium, 317–322
 - determination of, 320–322
 - hypernatremia, 319*t*, 320, 638*t*, 660
 - hyponatremia, 318–320
 - and osmolality, 316
 - in pediatric patients, 660
 - reference range of, 322*t*
 - regulation of, 318, 339, 522
 - in renal function, 522

- specimens for, 320
 - in sweat, 544, 563, 564
 - in total parenteral nutrition, 637
- Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 159
- Sodium loss, increased, 318
- Software programs, 139
- Solid-phase fluorescence immunoassays (SPFIA), 157
- Solid-phase separation, 156
- Solubility of proteins, 189
- Solubility test, 391–392
- Solutes, 6
- Solutions, 6–8
 - buffers, 8
 - colligative properties of, 7
 - concentration of, 7, 20–23
 - conductivity of, 8
 - converting units of, 22–23
 - defined, 7
 - density of, 22
 - dilutions, 23–25
 - molality of, 7
 - molarity of, 7, 21
 - normality of, 7, 21–22
 - percent, 7, 20–21
 - pH of, 8
 - redox potential of, 8
 - saturation of, 7
 - specific gravity of, 22
 - supercooled, 118–119
- Solvents, 7, 109–110
- Somatomedins (See Insulinlike growth factors)
- Somatostatin (SS)
 - in glucose regulation, 267–268
 - in growth hormone release, 402, 403, 665
- Somatotropin (See Growth hormone)
- Sorbents, 109
- Southern blot, 162, 164
- SPE (serum protein electrophoresis), 207–208, 209, 210
- Specific gravity (SG), 22, 527
- Specificity
 - of enzymes, 239
 - in fluorometry, 100
 - statistical, 61–63, 64
 - in tumor markers, 608
- Specimens
 - chain of custody for, 31
 - collection of, 26–27, 69, t3–t6
 - for alcohols, 591
 - for ammonia, 231–232
 - amniotic fluid, 555
 - for bicarbonate, 326
 - for bilirubin, 483
 - for blood gas analysis, 358–360
 - for calcium, 334
 - for chloride, 325
 - for creatinine, 227, 524

- in elderly, 651
 - for lactate, 336–337
 - for lipids and lipoproteins, 305–306
 - for magnesium, 330
 - in pediatric patients, 657
 - for phosphorus, 336
 - pleural fluid, 565
 - for potassium, 324
 - for reference interval studies, 58
 - for sodium, 320
 - sweat, 544, 564
 - synovial fluid, 564
 - for therapeutic drug monitoring, 576–577
 - for trace elements, 366
 - for urea, 222–223
 - for uric acid, 230
 - urine, 28, 524, 526
 - for urobilinogen, 484
 - diagnostic, 39
 - evaporation of, 130, 657
 - identification of, 127
 - for point-of-care testing, 173
 - preparation of, 127
 - processing of, 29, 140–141
 - quality assurance of, 69–70
 - size of, 132
 - storage of, 29, 70
 - types of, 26–29
 - variables of, 29, 30*t*–31*t*, 31
- Spectral-mapping, 142
- Spectrometry, tandem mass, 113, 115, 669, 671
- Spectrophotometers
- atomic absorption, 97–98
 - light source of, 93–94
 - monochromators of, 94
 - photodetectors of, 94–96
 - quality assurance of, 96
 - sample cells of, 94
 - single and double-beam, 93, 95–96
- Spectrophotometry, 91–98
- atomic absorption, 97–98
 - in automated analyzers, 136
 - Beer's Law in, 91–93
 - for bilirubin, 483, 556–557
 - in blood gas measurements, 353–354
 - quality assurance in, 96
 - in slide technology, 137, 138
 - spectrophotometers in, 93–96
 - ultraviolet, 205
- Spermatogenesis, 437, 438
- Spermatogonia, 437
- Spermatozoa, 528
- SPFIA (solid-phase fluorescence immunoassays), 157
- Sphingomyelin (SP), 558
- Spills
- of biohazardous materials, 38

- chemical, 41
- mercury, 40
- SpO₂ (pulse oximetry), 352
- Spot tests, 598
- Squamous cell carcinoma antigen (SCCA), 614
- 3SR (self-sustained sequence replication), 163
- SRM (standard reference materials), 5
- Staff, 169–171, 173, 174
- Standard deviation
 - defined, 51, 52
 - indices, 81
 - of mean, 52
 - of regression line, 55
- Standard error of the estimate, 44
- Standard error of the mean (SEM), 52–53
- Standard precautions, 39
- Standard reduction potentials, 102*t*
- Standard reference materials (SRMs), 5
- Standardization
 - in lipid analysis, 298, 304–306
 - in point-of-care testing, 171–172
- Standards
 - for calibration of automated analyzers, 138–139
 - for pH electrode, 358
 - primary, 5, 70
 - secondary, 5, 70
- Starch gel, 106
- Starch intolerance test, 545
- Statistical quality control system, 70, 71–72
 - control rules in, 72–79
 - defined, 70
 - general operation of, 71–72
 - patient data in, 79–81
- Statistics, 49–69
 - defined, 49
 - descriptive, 49–55
 - diagnostic efficacy, 61–63
 - inferential, 55–56
 - method selection in, 64–69
 - predictive value theory in, 61–63, 64
 - reference intervals in, 57–61
- Steatorrhea, 541, 543
- Stereoisomers, 264
- Stereoisometric specificity, 239
- Steric exclusion chromatography, 108
- Sterilization of water, 6
- Steroids, anabolic, 600
- Stokes shift, 98
- Stool fat, 543–544, 551
- Storage
 - of chemicals, 36–37, 40–41
 - equipment for, 36–37
 - of specimens, 29, 70
- Stray light, 96
- Stress, and atherosclerosis, 502
- Stress injury, and malnutrition, 629–630

Structure

- of amino acids, 180, 181 *t*
 - of carbohydrates, 263, 264, 265
 - of creatine, 224
 - of creatinine, 224
 - of enzymes, 237
 - of hemoglobin, 383–384
 - of lipids, 284
 - of lipoproteins, 285–287
 - of myoglobin, 393–394
 - of porphyrins, 378
 - of proteins, 187–188
 - quaternary, 188, 237
 - of urea, 220
- Subacute nonsuppurative thyroiditis, 454
- Subacute thyroiditis, 450, 454
- Subclinical hyperthyroidism, 449
- Subclinical hypothyroidism, 449
- Substitution balances, 16
- Substrate-level fluorescence immunoassays (SLFIA), 157
- Substrates
- concentration of, 239–240
 - defined, 238
 - relationship with enzyme and product, 239
- Sucrose, 265
- Sudan staining, 543
- Supercooled solutions, 118–119
- Supersaturated solutions, 7
- Supplies, laboratory (See Laboratory supplies)
- Surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry, 117, 118
- Surfactants, 558
- Surgery, 333, 514
- Sweat analysis, 542, 544, 563–564
- Sympathetic hyperactivity, 426
- Synchron analyzers, 125, 128 *t*
- Syncope, 498
- Syndrome of inappropriate ADH secretion (SIADH), 319
- Synovial fluid, 564
- Synthesis
- of carbohydrates, 479
 - of enzymes, 479–480
 - of fat, 479
 - of heme, 378–379
 - of hemoglobin, 384–385
 - of porphyrins, 378–379
 - of proteins, 191–192, 479
 - of thyroid hormones, 446–447
- Syringes, 15, 133, 360
- Systematic error (SE)
- constant, 54, 55
 - detection with control rules, 73, 74, 75–76
 - and inaccuracy, 64, 66
 - proportional, 54, 55
 - and single-value criteria, 68
 - in statistics, 54, 55, 70, 71
- Système International (SI) d'Unités, 3, 4 *t*, 675 *t*

T

- T₃ (triiodothyronine)
 - assays for, 449
 - free, 448, 449
 - protein-binding of, 448
 - synthesis of, 446–447, 664
- T₄ (tetraiodothyronine)
 - assays for, 449
 - free, 448, 450
 - in glucose regulation, 267
 - production of, 410
 - protein-binding of, 448
 - synthesis of, 446–447, 664
- Tablets, reagent, 132–133
- Tacrolimus, 583
- Tactoids, 386
- Tamm-Horsfall protein, 213–214
- Tandem mass spectrometry, 113, 115, 669, 671
- Tangier disease, 289, 298
- Tanner staging, 434
- TB (Tuberculosis), 39
- TBG (thyroxine-binding globulin), 447–448
- TBPA (thyroxin-binding prealbumin), 448
- TC (thermal conductivity) detectors, 113
- TC (to contain) pipets, 10–11
- TD (to deliver) pipets, 10–11
- TD₅₀, 589
- TDM (See Therapeutic drug monitoring)
- Teams, quality, 83
- Temperature
 - in blood gas analysis, 357–358
 - in enzymatic reactions, 240–241
 - measurement of, 9
- Teratogens, 40
- Teriparatide, 469, 472
- Tertiary hyperparathyroidism, 467–468
- Test packs, reagent, 133, 134
- Testes, 436–442
 - anatomy of, 436–437
 - disorders of sexual development, 438
 - hypofunction of, 438–441
 - hypogonadism, 441
 - injury and infection in, 440
 - physiology of, 437–438
 - testosterone replacement therapy, 441–442
- Testicular feminization syndrome, 439
- Testosterone
 - cellular mechanism of, 437
 - effect on secondary sexual effects, 438
 - effect on spermatogenesis, 438
 - in hypergonadotropic hypogonadism, 438–440
 - in hypogonadotropic hypogonadism, 440–441
 - in pediatric patients, 666
 - physiologic actions of, 437–438

- in postnatal development, 438
 - in prenatal development, 437–438
 - replacement therapy, 441–442
 - in testicular function, 436, 437
- Tetany, 331
- Tetrahydrobiopterin (BH₄), 182
- Tetrahydrocannabinol (THC), 600
- Tetraiodothyronine (See T₄)
- Tetralogy of Fallot, 499–500
- Tetrapeptides, 187
- Thalassemia, 387, 389–390
 - α-thalassemia, 389
 - β-thalassemia, 389–390
 - defined, 378, 384
 - diagnosis of, 390–393
 - major, 389, 390
 - minor, 389, 390
- THC (tetrahydrocannabinol), 600
- Thecal cells, 432
- Theophylline, 582
- Therapeutic drug monitoring (TDM), 571–583
 - absorption in, 571–572
 - administration routes in, 571
 - of antibiotics, 579–580
 - of antiepileptic drugs, 580–581
 - of antineoplastics, 583
 - of bronchodilators, 582
 - of cardioactive drugs, 577–579
 - drug distribution in, 572, 575
 - drug elimination in, 572–575, 651–652
 - in elderly, 651–652
 - free vs. bound drugs in, 572
 - of immunosuppressive drugs, 582–583
 - indications for, 571
 - metabolic clearance in, 574–575
 - peak and trough levels, 575
 - in pediatric patients, 671*t*, 672
 - pharmacokinetics in, 575–576, 688*t*–689*t*
 - of psychoactive drugs, 581–582
 - renal clearance in, 575
 - sample collection for, 576–577, *t*₅–*t*₆
 - steady state oscillation, 575–576
 - toxicology of, 597–598
- Therapeutic range, 572
- Thermal conductivity (TC) detectors, 113
- Thermistor probes, 9
- Thermometers, 9
- Thiamine, 619*t*, 622
- Thiazide diuretics, 465, 469
- Thick and thin film technology, 125, 357
- Thin-layer chromatography (TLC), 109–110
 - of amniotic fluid, 558, 559
 - in drug screening, 589, 599
- Thirst
 - antidiuretic hormone and, 522

- and hyponatremia, 319
- in regulating osmolality, 315, 316
- Thoracentesis, 565
- Thrombolytic agents, 513
- Thyroglobulin, 446, 449
- Thyroid cancer, 453, 454
- Thyroid gland, 446–454
 - anatomy and development of, 446–448
 - control of thyroid function, 448
 - disorders of, 450–454
 - amiodarone induced thyroid disease, 453–454
 - in elderly, 647
 - Graves' disease, 451–453
 - hypothyroidism, 446, 450–451
 - multinodular goiters, 453
 - nonthyroidal illness, 454
 - subacute thyroiditis, 450, 454
 - thyroid nodules, 454
 - thyrotoxicosis, 448, 451, 452*t*
 - toxic adenomas, 453
 - evaluation of, 448–450
 - antibodies, 449
 - fine-needle aspiration, 450
 - radioactive iodine uptake, 449–450
 - T₄ and T₃, 449
 - thyroglobulin, 446, 449
 - thyroid autoimmunity, 449
 - thyrotropin, 448–449
 - ultrasound, 450
 - hormones of, 331, 446–448
- Thyroid hormone
 - actions of, 448
 - protein-binding of, 447–448
 - synthesis of, 446–447
- Thyroidal peroxidase (TPO), 446
- Thyroid-binding proteins, 447–448
- Thyroiditis
 - chronic lymphocytic, 449
 - de Quervain's, 454
 - painful, 454
 - postpartum, 454
 - subacute, 450, 454
 - subacute nonsuppurative, 454
- Thyroid-releasing hormone (TRH), 401, 448
- Thyroid-stimulating hormone (TSH) (See Thyrotropin)
- Thyrotoxicosis, 451
 - disorders associated with, 453*t*
 - and Graves' disease, 449, 451–453
 - symptoms and signs of, 448, 452*t*
- Thyrotropin (TSH)
 - assays for, 448–449
 - in diurnal rhythms, 402
 - in hypothyroidism, 450
 - and radioactive iodine uptake, 450
 - secretion of, 401, 664
 - in thyroid hormone synthesis, 446

- in thyroid regulation, 402, 448
- Thyrotropin-releasing hormone (TRH), 401, 448, 664
- Thyroxin (See T₄)
- Thyroxine-binding globulin (TBG), 447–448, 664
- Thyroxine-binding prealbumin (TBPA), 448
- TIBC (total iron binding capacity), 368*t*, 369
- Timing of specimens, 28, 576
- TLC (See Thin-layer chromatography)
- TnI (troponin I), 200, 201, 246, 507
- TnT (troponin T), 200, 202, 246, 507
- Tocopherols, 620
- Tonometry, 360
- Total carbon dioxide content (ctCO₂), 358
- Total iron binding capacity (TIBC), 368*t*, 369
- Total iron content, 367*t*, 368–369
- Total laboratory automation (TLA), 140–142
 - chemical analyses in, 141
 - data management in, 142
 - sample processing in, 140–141
- Total nitrogen, 203–204
- Total parenteral nutrition (TPN), 636–638
 - electrolytes in, 637
 - minerals in, 637
 - panel testing in, 638
 - trace elements in, 637–638
 - urine testing in, 637
- Total proteins
 - abnormalities of, 202, 203*t*
 - analysis of, 204–205
 - Biuret method, 205
 - dye binding, 205
 - Kjeldahl method, 204
 - refractometry, 204
 - ultraviolet absorption, 205
 - in cerebrospinal fluid, 214–215
 - in urine, 211–214
- Total solids meter, 527
- Toxic adenomas, 453
- Toxicity (See *also* Toxicology)
 - acute and chronic, 589
 - from hazardous substances, 40
 - to lead, 594–595
 - of vitamin A, 620
 - of vitamin D, 464, 622
 - of vitamin K, 622
 - of zinc, 365*t*, 371
- Toxicology, 588–601
 - of abused drugs, 598–599
 - of acetaminophen, 597–598
 - acute and chronic toxicity, 589
 - of alcohol, 589–592
 - of amphetamines, 599–600
 - of anabolic steroids, 600
 - analysis of toxins, 589
 - of cannabinoids, 600

- of carbon monoxide, 592–593
 - of caustic agents, 593
 - of cocaine, 600–601
 - of cyanide, 593
 - defined, 588
 - dose response relationship in, 588–589
 - exposure to toxins in, 588
 - of metals, 593–596
 - of opiates, 601
 - in pediatric patients, 672
 - of pesticides, 596–597
 - of phencyclidine, 601
 - of salicylates, 597
 - of sedative hypnotics, 601
 - of therapeutic drugs, 597–598
- TPN (See Total parenteral nutrition)
- TPO (thyroidal peroxidase), 446
- Trabecular bone, 462
- Trace elements, 365–373
- chromium, 365*t*, 371
 - cobalt, 365*t*, 371
 - copper, 365*t*, 369–370
 - defined, 365
 - essential, 365*t*
 - fluoride, 371–372
 - function and abnormalities of, 365*t*
 - general considerations for, 366
 - iron, 365*t*, 366–369
 - manganese, 365*t*, 372
 - molybdenum, 365*t*, 372–373
 - reference values for, 365*t*
 - selenium, 365*t*, 373
 - and total parenteral nutrition, 637–638
 - ultratrace, 365
 - zinc, 365*t*, 370–371
- Tracers, 152, 153
- Training for POCT, 171, 174
- Tranquilizers, 601
- Transaminases, 250, 484–485
- Transcutaneous monitoring, 142, 355, 659
- Transfer pipets, 11*t*, 12–13
- Transferases, 237, 238*t*, 250
- Transferrin receptors (circulating TrfR), 368
- Transferrin saturation, 367*t*, 368*t*, 369
- Transferrin (siderophilin)
- characteristics of, 190*t*, 197
 - and iron, 367*t*, 368*t*, 369
 - in nutritional assessment, 634
- Transfusion, intrauterine, 556
- Transmittance, percent (%T), 92, 93, 682*t*–683*t*
- Transmyocardial laser revascularization, 514
- Transplantation
- heart, 514
 - kidney, 535–536
- Transport
- active, 315

- of copper, 369
 - of iron, 366, 367
 - of oxygen, 351–352
 - of zinc, 370
- Transthyretin (TTR)
- in cerebrospinal fluid, 562
 - in nutritional assessment, 634–635
 - as plasma proteins, 190*t*, 193
- Transudates, 565
- Tray carrier for analyzers, 129
- TRH (thyrotropin-releasing hormone), 401, 664
- Tricarboxylic acid (TCA) cycle, 265, 266
- Tricyclic antidepressants (TCAs), 581–582
- Triglycerides
- absorption of, 288
 - analysis of, 299–300
 - analytic performance goals for, 292*t*
 - chemistry of, 284
 - endogenous, 287
 - hypertriglyceridemia, 295–296
- Triiodothyronine (See T₃)
- Trinder reaction, 275, 597
- Trioses, 263
- Tripeptides, 187
- Tropic hormones, 402, 403*t*
- Troponin complex, 200–201, 246, 507
- Trough drug level, 575
- Trousseau's sign, 466
- True negatives (TN), 62
- True positives (TP), 62, 63
- TSH (See Thyrotropin)
- TSH receptor antibodies, 449
- t-test, 55–56, 67
- TTR (See Transthyretin)
- Tuberculosis (TB), 39
- Tubes
- evacuated, 26, 27, 28*t*
 - photomultiplier, 95
- Tubular proteinuria, 213
- Tubular reabsorption, 339, 520
- Tubular secretion, 520
- Tubules, renal (See Renal tubules)
- Tumor markers, 608–614
- β₂-microglobulin, 612
 - cancer antigen 15-3, 613
 - cancer antigen 19-9, 613
 - cancer antigen 125, 612
 - in cancer screening, 608
 - carcinoembryonic antigen, 613
 - carcinoembryonic proteins, 610–611
 - cell-specific, 611
 - chromogranin A, 426, 428, 613
 - in detection of recurrence, 609
 - in determining prognosis, 609
 - in early detection, 609

- enzymes, proteins, hormones, 609–610
- estrogen receptor, 613
- α -fetoprotein, 608, 612
- half-life of, 612
- homovanillic acid, 613–614
- and hook effect, 612
- human chorionic gonadotropin, 613
- lipid-associated sialic acid in plasma, 614
- in monitoring treatment, 608–609
- monoclonal defined, 611
- neuron-specific enolase, 614
- nonspecific, 611
- ordering recommendations, 612
- progesterone receptor, 614
- prostate-specific antigen, 608, 614
- specificity and sensitivity of, 605
- squamous cell carcinoma antigen, 614
- susceptibility genes, 608
- in target therapy, 609
- for thyroid cancer, 449
- vanillylmandelic antigen, 614
- Tumorigenesis, 605
- Tumors (*See also* Cancer)
 - of adrenal glands, 424, 426, 428, 429
 - benign and malignant, 605
 - in hypercalcemia, 464–465
 - islet-cell, 397, 540
 - of liver, 480–481
 - of pancreas, 274, 540, 613
 - of pituitary, 404, 405, 406, 407–408
- Turbidimetry, 100, 150–151
- Turbidity of specimens, 29, 526
- Turner's syndrome, 434
- Two-dimensional chromatography, 186
- Two-dimensional electrophoresis, 116
- Type 1 diabetes mellitus, 269, 271, 532, 662
- Type 2 diabetes mellitus, 269–270, 271, 532, 662
- Tyrosinemia, 183–184

U

- Ulcers, 548
- Ultracentrifugation, 300, 302
- Ultrafiltration of water, 6
- Ultra-short feedback loop, 401
- Ultrasounds, thyroid, 450
- Ultratrace elements, 365
- Ultraviolet light, 205, 383
- Ultraviolet oxidation, 6
- Uncompetitive inhibition, 241, 242
- Units of measure, 3, 4*t*
- Urea, 220–223
 - analysis of, 221–222, 223*t*
 - biochemistry of, 220
 - clearance of, 525
 - disease correlations with, 220–221
 - elimination of, 521

- interfering substances, 222–223
 - in pediatric patients, 663
 - reference intervals, 223
 - specimen requirements, 222–223
- Urea nitrogen (urea N), 220 (*See also* Urea)
- Urea nitrogen/creatinine ratio, 221
- Uremia, 220
- Uremic syndrome, 220, 532, 535–536
- Uric acid, 227–230
 - analysis of, 229–230
 - biochemistry of, 227–228
 - disease correlations, 228–229
 - elimination of, 522
 - interfering substances, 230
 - in pediatric patients, 663
 - reference interval for, 230
 - specimen requirements, 230
- Urinalysis (UA), 526–529
 - chemical analysis in, 527–528
 - physical characteristics in, 526–527
 - sediment examination in, 528–529
 - bacteria in, 528
 - casts in, 528–529
 - cells in, 528
 - crystals in, 529
 - miscellaneous elements, 528
 - specimen collection in, 526
 - in total parenteral nutrition, 637
- Urinary tract infections/obstructions, 531
- Urine (*See also* Urinalysis)
 - in alkaptonuria, 184
 - amino acid analysis in, 186
 - appearance of, 526
 - bacteria in, 527, 528, 531
 - bilirubin in, 528
 - calcium in, 334
 - casts in, 528–529
 - cells in, 528
 - collection of, 28, 212, 524
 - cortisol in, 420
 - crystals in, 529
 - in cystinuria, 186, 529
 - drugs in, 598
 - electrophoresis of, 525
 - glucose in, 271, 527, 637
 - hemoglobin in, 528
 - in homocystinuria, 185, 529
 - ketones in, 278, 527
 - lipids in, 530
 - in maple syrup urine disease, 184–185
 - metanephrines in, 426
 - microalbumin in, 213, 279, 525–526, 533
 - odor of, 526
 - osmolality of, 317, 320
 - pH of, 527
 - in phenylketonuria, 182–183

- porphyrins in, 381
- potassium in, 417
- proteins in, 211–214, 527
- specific gravity of, 527
- turbidity of, 526
- urobilinogen in, 484, 528
- volume of, 526–527

Urobilinogen

- analysis of, 483–484
- in feces, 484
- in liver physiology, 478
- in urine, 484, 528

Uroporphyrin (URO), 378

User Demonstration of Precision and Accuracy, 68–69

V

Vaccine for hepatitis B, 487

Valence, 7

Validation of POCT, 173

Valproic acid, 581

Vancomycin, 579–580

Vanillylmandelic acid (VMA), 425, 426, 614

Vapor pressure, 7

Vapors, toxic, 40

Variations, analytical, 49

Variagate porphyria (VP), 379

Vasoactive inhibitory peptide (VIP), 414

Vasodilators, 512, 513*t*

Vasopressin (See Antidiuretic hormone)

Veins, portal, 476

Velocity of enzymatic reactions, 239–240

Venipuncture, 26–28, 657

Ventricular septal defects (VSD), 498–499

Very-low-density lipoproteins (VLDL)

- characteristics of, 286*t*, 287
- electrophoresis of, 197
- function of, 283

Vesicle monoamine transporters (VMAT), 424

Vessels, 10, 11*t*, 15

Villi

- arachnoid, 561
- intestinal, 549

VIP (vasoactive inhibitory peptide), 414

Viral hepatitis (See hepatitis)

Virilization, 432

Viruses, and heart disease, 505

Vitamin A, 465, 619*t*, 620

Vitamin B₁ (thiamine), 619*t*, 622

Vitamin B₂ (riboflavin), 619*t*, 622–623

Vitamin B₃ (pantothenic acid), 626

Vitamin B₆ (pyridoxine), 619*t*, 623

Vitamin B₁₂, 619*t*, 624–625

Vitamin C (ascorbic acid), 619*t*, 626

Vitamin D, 621–622

- in calcium metabolism, 458–460, 464

- deficiency of, 619*t*, 622
 - hypervitaminosis D, 464
 - hypovitaminosis D, 467
 - mechanism of action, 459
 - and renal function, 524
 - and rickets, 470, 618, 622
 - synthesis of, 458, 459
- Vitamin D₃, 331, 332
- Vitamin D-binding protein, 196
- Vitamin E, 619*t*, 620–621
- Vitamin K, 619*t*, 622
- Vitamins, 618–627 (*See also specific vitamins*)
- chemical determinations of, 619–620
 - deficiencies of, 618–620
 - effect of drugs and contraceptives on, 627*t*
 - factors affecting metabolism of, 626–627
 - fat-soluble, 619, 620–622
 - insufficiency/dependency of, 618–619
 - recommended dietary allowances of, 626
 - in special diets, 627
 - storage in liver, 479
 - water-soluble, 619, 622–626
- Vitros analyzers
- features of, 128*t*
 - history of, 125
 - ISE system in, 321–322
 - mixing in, 134
 - probe in, 130, 132
 - reagents in, 133
 - sample cup trays in, 129
 - separation in, 135
 - and total laboratory automation, 141
- VLDL (*See* Very-low-density lipoproteins)
- VMA (vanillylmandelic acid), 426, 427, 614
- Voltametry, anodic stripping, 105
- Volume
- blood, 316–317
 - of drug distribution, 572
 - of pipets, 10–11
 - of urine, 526–527
- Volumetric flasks, 10, 11*t*
- Volumetric pipets, 12, 13
- Von Gierke disease, 274
- VP (variegate porphyria), 379

W

- Waist-hip ratio, 648
- Waived tests, 169, 170*t*
- Waldenström's macroglobulinemia, 199
- Waste disposal, 44–45
- Water
- balance, 522, 660
 - deficit of, 316–317
 - deionized, 5, 6
 - distilled, 5, 6
 - and electrolytes, 315–317

- excess intake of, 316, 319
 - filtration of, 5–6
 - imbalance of, 319
 - increased retention of, 319
 - and osmolality, 315–316
 - reagent grade, 5, 6
 - RO (reverse osmosis), 5, 6
 - specifications for, 5–6
 - types I, II, III, 5, 6
- Water of hydration, 25–26
- Water-soluble vitamins, 622–626
- ascorbic acid, 626
 - biotin, 625–626
 - carnitine, 626
 - folate, 623–624
 - niacin, 623
 - pantothenic acid, 626
 - pyridoxine, 623
 - riboflavin, 622–623
 - symptoms of deficiencies, 619t
 - thiamine, 622
 - vitamin B₁₂, 624–625
- Watson-Schwartz test, 382
- Wavelength, 91, 96
- Waxy casts, 529
- Weight
- atomic, 684t–685t
 - and cardiac disease, 511
 - of children, 656
 - loss of, 623
- Western blot, 158–159
- Westgard multirule procedure, 73, 75–79, 80
- White blood cell casts, 529
- White blood cells, in urine, 528
- Whole blood, 27
- Wilson's disease, 196, 370
- Wolff-Chaikoff effect, 454

X

- Xanthochromia, 561
- Xanthomas, 294
- Xenobiotics, 574
- D-xylose absorption test, 545, 550–551

Y

- Yeast cells, 528

Z

- Zeeman effect, 98
- Zeitgeber, 401–402
- Zero-order kinetics, 239, 242
- Zinc, 370–371
 - absorption, transport, excretion of, 370
 - biochemical functions of, 365t, 370–371
 - deficiency of, 365t, 371
 - dietary requirements of, 370

INDEX

laboratory evaluation of, 371
reference values of, 365*t*
and total parenteral nutrition, 637, 638
toxicity of, 365*t*, 371
Zinc protoporphyrin (ZPP), 381, 383
Zollinger-Ellison syndrome, 540, 548, 549
Zona fasciculata, 414
Zona glomerulosa, 414
Zona reticularis, 414
Zone electrophoresis, 105, 211
ZPP (erythrocyte zinc protoporphyrin), 381, 383
Zymogen, 237

INDEX